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Prostate cancer (PCa) has emerged as the most commonly diagnosed lethal cancer in 
European men. PCa is a heterogeneous cancer that in the majority of the cases is slow 
growing: consequently, these patients would not need any medical treatment. Current 
diagnostic methods of PCa suffer from a lack of sensitivity and specificity that may cause 
either missed cancers or overtreatment as a consequence of over-diagnosis. Therefore, 
more reliable biomarkers are needed for a better discrimination between indolent and 
potentially aggressive cancers.   
The aim of this thesis was the identification and validation of novel biomarkers for PCa. 
The mRNA expression level of 14 genes including AMACR, AR, PCA3, SPINK1, 
TMPRSS2-ERG, KLK3, ACSM1, CACNA1D, DLX1, LMNB1, PLA2G7, RHOU, SPON2, 
and TDRD1 was measured by an absolutly quantitative reverse transcription PCR in 
prostate tissue samples from men with and without PCa. For the last eight genes, the 
function in PCa progression was studied by a specific siRNA knockdown in PC-3 and 
VCaP cells. 
The results showed statistically significant overexpression for all the target genes, except 
for KLK3 in men with PCa compared with men without PCa. Interestingly, AMACR 
mRNA expression was similarly upregulated in all samples from men with PCa even if 
taken from apparently histologically benign areas; thus pointing to potential “field 
effects” in cancer-adjacent or associated tissues. Significant differences were observed 
in low versus high Gleason grades (for PLA2G7), PSA relapse versus no relapse (for 
SPON2), and low versus high TNM stages (for CACNA1D and DLX1). The knockdown 
by siRNA resulted in a cytotoxic effect for DLX1, PLA2G7, and RHOU silencing; 
furthermore, a cell invasion alteration was caused by PLA2G7, RHOU, ACSM1, and 
CACNA1D silencing in 3D. TDRD1 and TMPRSS2-ERG expression was useful in 
discriminating between men with and without PCa even when applied to apparently 
benign prostate tissue biopsies from men with a clinical suspicion of PCa. Utilizing a 
multivariate analysis using RNA expression of 12 genes in combination with serum 
PSA, F/T PSA, and prostate volume outperformed each individual marker in 
distinguishing aggressive PCa from indolent disease. Altogether, these findings indicate 
the possibility of utilizing these new markers as diagnostic and prognostic markers, and 




Eturauhassyöpä on yleisin eurooppalaisilla miehillä diagnosoitu, kuolemaanjohtava 
syöpä. Se on heterogeeninen tauti, joka useimmissa tapauksissa etenee hitaasti eikä siten 
välttämättä vaadi lääketieteellistä hoitoa. Eturauhassyövän diagnosoinnissa käytetyt 
menetelmät eivät kuitenkaan ole tarpeeksi herkkiä ja spesifisiä, joten monet syöpä-
tapaukset voivat jäädä huomaamatta, tai toisaalta joitakin tapauksia voidaan ylihoitaa 
tarpeettomasti. Luotettavampia biomerkkiaineita tarvitaan, jotta sekä hidaskasvuiset että 
myös mahdollisesti aggressiivisiksi osoittautuvat syövät voidaan tunnistaa. 
Tämän väitöskirjatyön tavoitteena oli löytää ja validoida uusia biomerkkiaineita 
eturauhassyövän diagnostiikkaan. Neljäntoista geenin – AMACR:n, AR:n, PCA3:n, 
SPINK1:n, TMPRSS2-ERG:n, KLK3:n, ACSM1:n, CACNA1D:n, DLX1:n, LMNB1:n, 
PLA2G7:n, RHOU:n, SPON2:n ja TDRD1:n – lähetti-RNA-tasoja mitattiin täysin 
kvantitatiivisella käänteiskopiointi-PCR-määrityksellä sekä eturauhassyöpää 
sairastavien että sairastamattomien miesten kudosnäytteistä. Viimeksi mainittujen 
kahdeksan geenin osalta tutkittiin myös niiden osuutta eturauhassyövän etenemisessä 
vaimentamalla siRNA-molekyylien avulla niiden toimintaa PC-3- ja VCaP-soluissa. 
Kaikki tutkitut geenit KLK3:a lukuunottamatta yli-ilmenivät tilastollisesti merkittävästi 
miehillä, jotka sairastivat eturauhassyöpää. Kiinnostavaa oli myös, että AMACR-RNA:n 
ilmeneminen oli lisääntynyt kaikissa eturauhassyöpäpotilaiden näytteissä – myös niissä, 
jotka olivat peräisin näennäisesti hyvänlaatuisilta kudosalueilta, mikä viittaisi mah-
dolliseen kenttävaikutukseen syöpäkudoksen läheisyydessä olevissa kudoksissa. 
Tilastollisesti merkittäviä ilmenemistasojen muutoksia havaittiin Gleason-asteeltaan 
(PLA2G7) tai TNM-luokitukseltaan (CACNA1D ja DLX1) korkeiksi luokitelluissa 
kudoksissa sekä PSA-relapsipotilaiden kudoksissa (SPON2). DLX1:llä, PLA2G7:lla ja 
RHOU:lla havaittiin olevan sytotoksisia vaikutuksia ja PLA2G7:n, RHOU:n, ACSM1:n 
ja CACNA1D:n havaittiin vaikuttavan solujen invaasiokykyyn. TDRD1- ja TMPRSS2-
ERG-RNA-tasot auttoivat tunnistamaan eturauhassyöpätapauksia jopa hyvänlaatuisten 
eturauhaskoepalojen perusteella. Multivarianttianalyysi, joka yhdisti 12 geenin RNA-
tasot seerumin PSA- ja F/T PSA- tasoihin sekä eturauhasen kokoon, tunnisti 
aggressiiviset syövät paremmin kuin mikään yksittäinen merkkiaine. Kaiken kaikkiaan 
tässä työssä tehdyt havainnot viittaavat tutkittujen geenien olevan mahdollisesti 




1. LITERATURE REVIEW 
1.1. Normal prostate gland 
The prostate is one of the largest glands of the human reproductive system. It is shaped 
like an inverted pyramid, and in adults it is approximately the size of a chestnut/walnut. 
The prostate is located between the bladder and penis. The urethra passes through the 
central part of the prostate and transports body fluids from bladder to penis. The 
prostate’s secretions make up about 30% of seminal fluids in ejaculate, and have both 
protective and nourishing functions for the sperm. The prostate gland is composed of 
four zones (McNeal, 1968; McNeal, 1980): the transitional, central and peripheral zones 
as well as the anterior fibromuscular stroma. The transitional zone represents 
approximately 5% of the normal prostate; benign prostate hyperplasia (BPH), the benign 
enlargement of prostate, mainly occurs in this zone, whereas prostate adenocarcinoma is 
quite rare in this region. The central zone forms about one fourth of the prostate, and 
ejaculatory ducts are located in the middle of this zone. The peripheral zone makes up 
60-70% of the prostate gland; most of prostate adenocarcinomas arise within this zone, 
and prostatitis is also common. The fourth zone of prostate, the anterior fibromuscular 
stroma, constitutes the remainder, approximately 25-30%, of the prostate gland.  
1.2. Prostate diseases 
1.2.1. Prostatitis 
Prostatitis is an inflammation or infection of the prostate that sometimes also affects the 
area around the prostate. Prostatitis is the most common urinary tract problem in men 
below the age of 50 years, and it affects up to 15% of the male population in the United 
States (Murphy et al., 2009). Prostatitis is classified as acute bacterial prostatitis, 
bacterial or chronic pelvic pain syndrome, or asymptomatic prostatitis. Prostatitis can be 
very painful and may negatively affect the patient’s life quality. 
1.2.2. Benign prostate hyperplasia (BPH) 
BPH refers to the enlargement of prostate in men due to the proliferation of epithelial 
cells and smooth muscles within the transitional zone of the prostate. BPH is a 
progressive disorder, and patient age is the most important risk factor. The prevalence 
of BPH among men in their 40s is only about 25%, while it increases to > 90% in men 
older than 80 years (Sarma and Wei, 2012). BPH is not a life-threatening disease, but it 
can cause lower urinary tract symptoms, e.g., hesitancy (a delay between trying to urinate 
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and urine starting to flow), or cause frequent urination that can significantly reduce the 
patients' quality of life.    
1.2.3. Prostate cancer (PCa) 
Although adenocarcinoma of the prostate, or prostate cancer (PCa), has a much lower 
incidence rate than BPH, it is the most frequently diagnosed cancer type, and the second 
largest cause of cancer-related death in men. On the basis of a surveillance study 
conducted by American Cancer Society, it has been estimated that in 2015, over 200,000 
new PCa cases will be diagnosed. This equals 26% of the total number of newly 
diagnosed cancer cases in men in the US. 
In the early stages, PCa usually causes no symptoms. Nevertheless, patients with 
advanced PCa frequently suffer from urinary problems such as difficulty in starting or 
stopping the urine flow, a frequent need to urinate, painful urination and blood in the 
urine. Metastasized PCa commonly causes severe pain, mainly due to the spreading of 
cancer cells to the bone. 
1.2.3.1. Risk factors for PCa 
PCa is a multifactorial disease, and several genetic and non-genetic factors are involved 
in its initiation and progression. Age, family history and ethnicity are considered as the 
most important, prevalent risk factors for PCa. Aging is the predominant risk factor for 
PCa. On the basis of an age-specific study it has been shown that in the age-adjusted 
incidence curve the risk of PCa starts to rise in men above 55 years of age and it peaks 
at the age of 74 years, after which the statistical incidence rate begins to slightly decline 
(Gann, 2002). Only 10 to 20 percent of PCa cases are considered familial (Stanford and 
Ostrander, 2001), whereas 75 to 85 percent of PCa cases are sporadic (Stanford and 
Ostrander, 2001; Carter et al., 1993; Ostrander, Markianos and Stanford, 2004). 
However, another study performed on 44,788 pairs of twins revealed a 42% risk for 
heritable factors for PCa (Lichtenstein et al., 2000). There is also a 1.4 times higher risk 
of being diagnosed with PCa and two to three times higher risk of dying of the disease 
for African men compared to Caucasian men (Chornokur et al., 2011). In addition to risk 
factors mentioned above, several other factors such as diet, lifestyle, environmental 
factors, steroid hormones and body mass index may have a role in PCa development.  
1.2.3.2. Development of PCa 
Carcinogenesis is considered to be a complex process arising from the accumulation of 
different genetic changes and requiring several steps. On the basis of this hypothesis, it 
could be concluded that different stages and grades of PCa may be associated with 
specific and unique genetic alterations. These initiating genetic and genomic instabilities 
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are followed by a clonal selection process involving further genetic changes and giving 
tumor cells more capacity for autonomy. Although several allelic losses related to PCa 
carcinogenesis have been reported, none of them have resulted in a conclusive 
designation of a single candidate tumor suppressor gene involved in the progression of 
PCa. 
The loss of specific regions in chromosome 8p, is common in patients with colorectal 
and lung cancer, has also been reported in approximately 80% of patients with prostate 
tumors (Chang et al., 1994; Fujiwara et al., 1994; Matsuyama et al., 1994; Imbert et al., 
1996; Wistuba et al., 1999). Several studies have suggested that a loss of 8p1-21 locus 
that encodes the NKX3.1 homeobox gene occurs in the primary precursor lesions in 
human PCa, prostate intraepithelial neoplasia (PIN) as well as early-stage PCa (Bhatia-
Gaur et al., 1999; Voeller et al., 1997). A loss of PTEN (Phosphatase And Tensin 
Homolog) caused by the loss of certain regions on chromosome locus 10q-23 has been 
reported in 50 to 80 percent of PCa cases in several independent studies (Saric et al., 
1999; Ittmann, 1996; Trybus et al., 1996; Cher et al., 1996).  A mutation of PTEN has 
also been frequently detected in metastasized PCa and, to a lesser degree, in localized 
PCa (McMenamin et al., 1999; Suzuki et al., 1998). A deletion or mutation of PTEN 
results in increased cell proliferation and reduced cell death. Retinoblastoma (RB) gene 
is another tumor suppressor for which genetic loss or mutations have been reported in 
about 50% of PCa patients (Cooney et al., 1996; Melamed, Einhorn and Ittmann, 1997). 
A loss of a region of chromosome 17p, which includes the p53 gene occurs preferentially 
in the advanced stages of PCa and is associated with progression to metastatic disease 
(Cher et al., 1994; Saric et al., 1999; Brooks et al., 1996). It has been reported that 
acquisition of TP53 mutations is linked with the expansion of metastatic subclones 
(Hong et al., 2015). Moreover, association of the amplification of MYCL in evolution 
of multifocal PCa has been demonstrated (Boutros et al., 2015). 
In addition to the deletion and mutation of tumor suppressor genes, several other genetic 
changes in different pathways can occur, for example, mutation, overexpression or 
amplification of cell cycle regulatory genes, androgen receptor signaling pathway genes, 
apoptotic regulatory genes and genes involved in telomerase activity. These changes are 
involved in the initiation and progression of prostate adenocarcinoma (Zhang et al., 
1998; Shen and Abate-Shen, 2010).  
1.2.3.3. Histology and grading of PCa 
Due to the heterogeneous and multifocal nature of PCa, its grading is a challenging issue 
for pathologists. A cancerous prostate normally consists of a juxtaposition of benign 
tissue, PIN foci and neoplastic (cancerous) foci with different grades.   
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PIN is identified as the primary progenitor for prostatic adenocarcinoma. PIN manifests 
either as low-grade (LGPIN) or high-grade (HGPIN). Since LGPIN shares common 
structures with normal prostate, it is not considered as PCa precursor (Bostwick, 2000). 
Although some studies have reported the presence of cancer in repeated biopsies for 
LGPIN cases (Goeman et al., 2003) it has been suggested that mentioning LGPIN in 
diagnostic reports be avoided (Srigley et al., 2000). According to several studies, HGPIN 
is the most frequent and most relevant precursor lesion for prostate adenocarcinoma 
(Singh et al., 2009; Powell et al., 2010; Dovey, Corbishley and Kirby, 2005; Joniau et 
al., 2005; Vis and Van Der Kwast, 2001; Gaudin et al., 1997; Pacelli and Bostwick, 
1997). HGPIN exhibits several similarities with PCa, including molecular, biochemical 
and cytological changes (Vis and Van Der Kwast, 2001). Furthermore, increased HGPIN 
with age incidence, its occurrence predominantly in the peripheral zone of the prostate 
and pronounced multifocality are other similarities between HGPIN and PCa (Joniau et 
al., 2005; Brawer, 2005). 
As in many other diseases, histopathology is the gold standard method for the diagnosis 
and staging of prostate adenocarcinoma. The Gleason grading system has remained the 
most widely used method for prostate adenocarcinoma grading since its introduction in 
1966 by Donald F. Gleason (Gleason, 1966). Gleason grading is based on the 
microscopic examination of glandular architecture in hematoxylin and eosin-stained 
histological slides (H&E stain). In this system, glandular tissue architecture is divided 
into five characteristic patterns or tissue architectures, based on the level of growth and 
differentiation that is identified by numbers from 1 (most differentiated) to 5 (the least 
differentiated). The final Gleason score is the sum of predominant and the second most 
prevalent patterns, ranging from 2 to 10.  
Furthermore, TNM classification is the most widely used staging system for PCa. TNM 
assesses the extent of the primary tumor (T category), the extent of involved lymph nodes 
(N) and any distant metastasis (M). Moreover TNM staging in PCa takes the cancer 
grade into account (Tables 1 and 2).  
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Table 1. TNM classification of PCa 
Category to be 
assessed 
Stage    Definition 
Primary tumor 
(Clinical) 
TX Primary tumor cannot be assessed 
T0 No evidence of primary tumor 
T1 Clinically inapparent tumor not palpable or visible by imaging 
T1a Tumor incidental histologic finding in ≤5% of tissue resected 
T1b Tumor incidental histologic finding in >5% of tissue resected 
T1c Tumor identified by needle biopsy (because of elevated PSA level) 
T2 Tumor confined within prostate; tumors found in 1 or both lobes by 
needle biopsy but not palpable or reliably visible by imaging 
T2a Tumor involves one half of 1 lobe or less 
T2b Tumor involves more than one half of 1 lobe but not both lobes 
T2c Tumor involves both lobes 
T3 Tumor extends through the prostatic capsule; invasion into the 
prostatic apex, or the prostatic capsule is classified not as T3 but as 
T2 
T3a Extracapsular extension (unilateral or bilateral) 
T3b Tumor invades seminal vesicle(s) 
T4 Tumor fixed or invades adjacent structures other than seminal 




pT2a Unilateral, involving one half of 1 lobe or less 
pT2b Unilateral, involving more than one half of 1 lobe but not both lobes 
pT2c Bilateral disease 
pT3 Extraprostatic extension 
pT3a Extraprostatic extension or microscopic invasion of the bladder 
neck 
pT3b Seminal vesicle invasion 
pT4 Invasion of the bladder and rectum 
Regional lymph 
nodes (clinical) 
NX Regional lymph nodes were not assessed 
N0 No regional lymph node metastasis 




PNX Regional nodes not sampled 
pN0 No positive regional nodes 
pN1 Metastases in regional nodes(s) 
Distant 
metastasis (M) 
M0 No distant metastasis 
M1 Distant metastasis 
M1a Non-regional lymph nodes(s) 
M1b Bone(s) 




Table 2. Prostate cancer anatomic stage/ prognostic groups, based on the 7th edition of American 
Joint Committee on Cancer (2009)  
Group T N M PSA ng/ml Gleason 
I T1a–c N0 M0 PSA <10 Gleason ≤6 
T2a N0 M0 PSA <10 Gleason ≤6 
T1–2a N0 M0 PSA X Gleason X 
IIA T1a–c N0 M0 PSA <20 Gleason 7 
T1a–c N0 M0 PSA ≥10 <20 Gleason ≤6 
T2a N0 M0 PSA <20 Gleason ≤7 
T2b N0 M0 PSA <20 Gleason ≤7 
T2b N0 M0 PSA X Gleason X 
IIB T2c N0 M0 Any PSA Any Gleason 
T1–2 N0 M0 PSA ≥20 Any Gleason 
T1–2 N0 M0 Any PSA Gleason ≥8 
III T3a–b N0 M0 Any PSA Any Gleason 
IV T4 N0 M0 Any PSA Any Gleason 
Any T N1 M0 Any PSA Any Gleason 
Any T Any N M1 Any PSA Any Gleason 
 
1.2.3.4. Clinical management of PCa 
Several treatment options are available for PCa but before any decision is made, the 
patient’s life expectancy, his overall health status and the characteristics of tumor should 
be assessed. The treatment of localized PCa, which has not yet spread to other organs, is 
more straight forward than that of metastasized PCa. The main treatment choices for PCa 
are: 
1- Active surveillance/watchful waiting 
In some patients with low risk PCa, especially at an advanced age, the cancer may never 
become life threatening and aggressive therapies can be avoided. Watchful waiting 
which has been studied in several randomized controlled trials (Bill-Axelson et al., 2011; 
Iversen, Madsen and Corle, 1995; Wilt and Brawer, 1994), requires regular check-ups 
where the time between visits varies from patient to patient. If the cancer shows any 
signs of growth or progression to more aggressive stages, additional treatment options 
will be considered.  
2- Radiation therapy 
The second most frequent treatment option is the use of radiation to specifically kill 
cancer cells. Radiation therapy includes external beam radiation therapy and interstitial 
prostate brachytherapy. In interstitial prostate brachytherapy wires, catheters, seeds, or 
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needles sealed with radioactive substances are implanted in the prostate (Zelefsky and 
Whitmore, 1997; Sogani et al., 1980). 
3- Radical prostatectomy 
The third choice is radical prostatectomy (RP) which is a surgical procedure to remove 
the entire prostate and, if necessary, also of nearby tissues such as seminal vesicles. 
Nowadays laparoscopic or robot-assisted techniques have replaced retropubic or 
perineal incision methods. RP is mainly recommended for patients with a low-grade and 
truly organ confined PCa with over  a 10-year life expectancy (Xu et al., 2000). 
4- Hormonal therapy 
In cases where the cancer has already metastasized at the time of diagnosis, where RP 
or radiation is not possible, or where a relapse after local treatment occurs, hormonal 
therapy is used. Hormonal or hormone-replacement therapy (castration) removes the 
male hormones or blocks their activation to stop the cancer cells’ growth. It can be 
performed with different methods including: 
- luteinizing hormone-releasing hormone analogues and antagonists that can stop 
the synthesis of hormones in the testicles (Zhang et al., 2007) 
-  anti-androgens that block the hormonal action of androgens  
-  orchiectomy or surgical castration, which is the surgical removal of the testicles.  
A systematic review and a meta-analysis of neo-adjuvant (hormone therapy given before 
other treatments) and adjuvant hormone therapy (hormone therapy that is given after 
other primary treatments) in localized or locally advanced PCa revealed a significantly 
increased overall survival at 5 and 10 years for adjuvant therapy following radiotherapy 
and a significant improvement in disease-specific survival and disease-free survival at 5 
years (Kumar et al., 2006). 
Chemotherapy 
Chemotherapy is using anti-cancer agents to kill cancer cells or stop their division 
irrespective of their location in the body. Chemotherapy is not considered as standard 
treatment for localized PCa. However, it is mainly used when the cancer does not 
respond to hormone therapy. Like hormonal therapy, chemotherapy will not cure PCa 
completely, but it can shrink the size of the primary tumor, reduce local and distant 
metastases, and generally slow down cancer growth, which will ideally turn PCa into a 
chronic disease. Furthermore, this may help to control some of the symptoms, e.g., pain 
or extend the patient’s life. Chemotherapy (treatment with drugs, e.g., docetaxel or 
Literature Review 
18 
paclitaxel) is really just used for the most advanced cancers when the patients’ life 
expectancy does not greatly exceed one year.  
1.2.3.5. AR and castration resistant prostate cancer (CRPC) 
The male sex hormones or androgens are steroid hormones and play a key role in the 
development of male phenotype during fetal life and puberty. In adults they control 
fertility and sexual behavior. Prostate cells are androgen-dependent for growth, 
differentiation and maintenance. Testosterone and 5α-dihydrotestosterone are the two 
essential androgens involved in the development and maintenance of the prostate gland. 
Androgen receptor (AR) is a transcription factor of the steroid receptor family, and acts 
as the primary mediator of androgen action. The activation of AR signaling pathway in 
the prostate results in cell growth and differentiation as well as the production of 
prostatic fluids. The schematic illustration of AR signaling pathway is shown in Figure 
1. 
 
Figure 1. Schematic illustration of AR signaling pathway in prostate. DHT: 5α-
dihydrotestosterone; fAR: free AR (in the absence of ligand); hsp: heat shock protein; ARE: 
androgen response elements; TF: transcription factors; and RNApol: RNA polymerase. 
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Since PCa cells are remarkably androgen dependent, all patients initially respond to 
androgen deprivation therapy (ADT). However, after treatment for 2–3 years, most 
patients will develop resistance to these traditional hormonal approaches. Some patients 
will respond initially to secondary hormonal manipulations before the unavoidable 
formation of castration-resistant prostate cancer (CRPC). Several mechanisms leading 
to castration-resistant behavior are known, and these enable the tumor cells to survive 
and grow under androgen-depleted conditions. Some of the mechanisms are listed 
below:  
a)  The bypass of the AR signaling pathway: the autocrine production by epithelial 
cells of some growth factors, such as FGF and IGF1 (which are normally secreted 
by stromal cells in response to androgens) and the activation of oncogenes and 
inhibition of tumor suppressor genes are additional molecular mechanisms that 
tumor cells may apply to bypass the AR pathway (Cheng et al., 2007; Cooperberg 
et al., 2012; Heidenreich et al., 2014; Altman et al., 2012), whereas the 
amplification and overexpression of AR have been reported in androgen-
independent cancers, compared to primary tumors (Massoner et al., 2013; Celis 
et al., 2009; Pascal et al., 2009; Koivisto et al., 1997; McEntee et al., 1996; 
Epstein, 1994);  
b)  The de novo synthesis of androgens or converting steroids to testosterone (Srigley 
et al., 2000; Zoladz and Diamond, 2013; Wilkes and Tasker, 2014; Patel et al., 
2004);  
c)  AR mutation (Stamey, 2001), ligand-independent transactivation, and coactivator 
or corepressor alteration are further alterations of the AR pathway. 
1.3. Diagnosis of PCa 
Current routine diagnostic tools to investigate the presence of PCa are: the PSA test that 
measures the level of PSA (prostate specific antigen) in blood, digital rectal examination 
(DRE), and transrectal ultrasonography (TRUS). However, the definite diagnosis needs 
to be confirmed by the histological examination of prostate biopsy cores or specimens 
obtained from operations. Recently, multiparametric magnetic resonance imaging 
(mpMRI) has been used to distinguish between life-threatening and non-life-threatening 
cancers of the prostate for PCa management. It has been reported that mpMRI is a much 
more powerful risk-stratification tool than the PSA test (Thompson and Pokorny, 2015). 
PSA is a member of the kallikrein-like family of serine proteases that is almost 
exclusively produced by the prostate gland; a portion of that can leak to the blood stream 
depending on the patient’s age and the condition of the prostate gland. However, 
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increased PSA levels are not specific to PCa and PSA may also be elevated in other, 
non-malignant prostate conditions, e.g., BPH and prostatitis. In 1986, the PSA blood test 
was approved by the US food and drug administration for the screening and follow-up 
of PCa patients (Stamey et al., 1987). The usefulness of PSA screening in decreasing the 
mortality rate of PCa has been reported earlier (McShane et al., 2006), but PSA test has 
also resulted in a large number of false positive results and over-diagnosis (McShane et 
al., 2005). Several studies have demonstrated that the majority of men diagnosed with 
clinically localized PCa will not, even without treatment, develop aggressive and lethal 
forms of PCa (Rubio-Briones et al., 2014; Brooks, 2013). For this group of patients, only 
active surveillance would be enough. The histological examination of biopsies is also 
used to confirm the clinical suspicion for PCa and it is usually performed on a sequence 
of 6-12 tissue biopsy cores. However, these may not truly represent the whole gland and 
the suspicious lesion may be missed in biopsies leading to a false negative diagnosis or 
under-grading and, thus, a clear diagnostic and prognostic evaluation of the cancer risk 
may be compromised. Therefore, new biomarkers are needed to compliment the current 
diagnostic tools to facilitate the early diagnosis of PCa. Most importantly, such new 
markers should help in discriminating between indolent and aggressive cancer 
phenotypes and to provide a more specific, personalized prognosis.  
1.3.1. Different biomarkers for PCa 
Different definitions for biomarkers have been stated. Mueller defines biomarkers as 
“any measurable cellular, biochemical or molecular alterations in biological media such 
as human tissues, cells, or fluids (Felix et al., 2014)”. On the basis of the definition 
suggested by the National Institute of Health (NIH) a biomarker is a measurable 
characteristic that is an indicator of normal biological processes, pathogenic processes, 
or pharmacologic responses to a therapeutic intervention (Taylor et al., 2013). This most 
recent definition of a biomarker covers a broader explanation and applies to any 
measurable cellular, molecular, morphological, or biochemical changes in biological 
matrices such as cells, human tissues, or fluids (Arem et al., 2013; Chiriaco et al., 2013). 
An ideal cancer biomarker should be able to distinguish between healthy individuals and 
patients. It should already be expressed or its expression should elevated at an early stage 
of the disease. It should be easy to measure, inexpensive, and useful in providing more 
precise predictions, and it should help to reduce mortality. Good reproducibility and the 
possibility to multiplex multiple markers are other characteristics of ideal cancer 
biomarkers.   
Disease biomarkers can be divided into different types on the basis of their application. 
Risk markers provide early evidence of the risk of disease in people that have not been 
diagnosed with the disease. The earliest risk markers for cancer studies belong to 
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inherited genetic abnormalities, e.g., BRCA1 and BRCA2 mutation in breast and PCa 
(Cao and Sun, 2013; Feng et al., 2013). Diagnostic markers such as PSA are used to 
identify cancer at an early stage in the general population with the objectives to identify, 
classify, and staging of the patients. Besides PSA, AMACR, PCA3, TMPRSS2-ERG and 
human kallikrein 2 (KLK2) are some of the well-known diagnostic marker candidates 
for PCa. Based on the European Association of Urology (EAU) Guidelines on PCa, 
DRE, serum PSA level and histopathological verification of adenocarcinoma in prostate 
biopsy cores or specimens from TURP are recommended as the main diagnostic tools 
for PCa (Heidenreich et al., 2014).  
PSA is a better predictor of PCa when compared to DRE or TRUS. A risk of 10–30% 
false negative results and missed cancers using TRUS guided biopsy has been reported 
by several studies (Barqawi et al., 2011; Stewart et al., 2001; Patel et al., 2004).  Already 
moderately increased PSA levels indicate a greater likelihood of PCa and therefore PSA 
has been extensively used in early detection of PCa. But using PSA test for population 
screening is highly controversial, because it results in excessive use of biopsies leading 
to overdiagnosis and overtreatment of non-aggressive cancers with serious adverse 
effects. It was recently reported by the European Randomised Study of Screening for 
Prostate Cancer that screening of PCa using PSA does result in a substantial reduction 
in prostate cancer mortality (Schroder et al., 2014). Due to excessive use of biopsies, 
with resulting high rate of overdetection and overtreatment, PSA does not support 
initiation of wide population-based screening. However, the current EAU guidelines for 
PCa recommend that early PSA testing should be offered to those men who are at 
elevated risk for PCa (e.g. men over 50 years of age, men over 45 years of age with a 
family history of PCa, and to African-Americans) (Heidenreich et al., 2014). 
Risk of PCa in men with PSA level between 0-4 ng/mL varies from 6.6 to 27%. PSA 
values between 4.0 and 10.0 ng/ml are called the “gray zone” and a positive predictive 
value of only 26% has been reported for PSA in this range (Catalona et al., 1994). This 
results in unnecessary biopsies, discomfort, anxiety, and the risk of infection for the 
remaining 75% of men. To improve the sensitivity and specificity of the PSA test 
different modifications of PSA test, such as PSA density (level of serum PSA/prostate 
volume), PSA velocity (absolute annual increase in serum PSA ng/mL/year), PSA 
doubling time (the exponential increase in serum PSA over time), free/total PSA ratio 
and Prostate Health Index (PHI) have been suggested. The use of a panel of kallikrein 
markers (total, free, and intact PSA, and human kallikrein 2 (KLK2)) to reduce the rate 
of unnecessary biopsies has been reported (Vickers et al., 2008). This concept, which is 
now commercially available as the 4Kscore® Test (OPKO Diagnostics, LLC), uses the 
previously mentioned panel of four kallikreins together with clinical information in an 
algorithm to calculate an individual’s risk for aggressive prostate cancer on prostate 
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biopsy. It has been shown that the 4Kscore test, as a follow-up test after abnormal PSA 
and/or DRE test results, can improve the specificity for predicting the risk of aggressive 
prostate cancer as well as reduce unnecessary prostate biopsies (Punnen, Pavan and 
Parekh, 2015; Konety et al., 2015). 
The Progensa PCA3 assay (Groskopf et al., 2006), a urine test that measures PCA3 
mRNA in post-DRE urine sediments and has been reported to be superior to total PSA 
and F/T PSA percentage for detection of PCa, is another test that is recommended by the 
EAU guidelines on PCa (Heidenreich et al., 2014). Recently several other tests such as 
Oncotype DX® (provides Genomic Prostate Score (GPS) and aggressiveness of PCa) 
(Klein et al., 2012), Polaris® (measures the aggressiveness of PCa) (Cuzick et al., 2011; 
Cooperberg et al., 2013), and Confirm MDx (addresses false-negative biopsy) (Stewart 
et al., 2013) have been developed to improve diagnosis and prognosis of PCa, but they 
are not recommended by EAU guidelines yet.  
AMACR is routinely used as a tissue biomarker to support the diagnosis of PCa. It is also 
useful for detection of small carcinoma foci in needle biopsies when combined with a 
basal cell marker such as keratin 5/6 or p63 (Jiang et al., 2002b; Jiang et al., 2002a; 
Kristiansen, 2009). TMPRSS2-ERG fusion detection in urine samples has resulted in 
90% specificity and 94% positive predictive value for PCa detection (Hessels et al., 
2007). The high specificity of the TMPRSS2-ERG test makes it a potential candidate to 
be served in the clinic as a viable biomarker for investigating the presence or absence of 
PCa (Perner et al., 2007). 
In contrast, prognostic markers are most useful for patients who already have been 
diagnosed with cancer. They are used to determine the risk of cancer progression, its 
progression towards increased aggressiveness, poor patient survival, and patterns of cancer 
recurrence. E-cadherin, MMP9, and VEGF are examples for PCa prognosis markers (Lee 
et al., 2013), although none of them are utilized in clinical practice yet. Predictive markers 
are particularly important because of their role in estimating the likelihood of specific 
treatment outcomes (due to the fact that response to treatment correlates with the presence 
or absence of that particular biomarker). In some cases, predictive markers may also be 
functionally involved in cancer progression towards more aggressive behavior, failure of 
therapy, and resistance to chemotherapy. For example, BCL-2 expression could be used as 
a biomarker to identify those PCa patients who may respond (or fail to respond) to taxane-
based chemotherapy (Ibrayev et al., 2013).  
1.3.2. Types of biological samples available for identification of PCa biomarkers  
Blood, urine, semen, and prostate tissue are the most frequently used and clinically 
available biological specimens that can be used in PCa biomarker identification. Blood 
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samples contain various amounts of human proteins that are diagnostically relevant, 
exosomes, and circulating cancer cells (CTC). All of these can be used for diagnoses that 
are based on proteins, DNA, or RNA. Urine samples, like blood, also contain exosomes 
and exfoliated cells. Due to the non-invasive nature of urine sampling, these samples 
have become particularly popular in protein, DNA, and RNA-based marker research. 
PCa biomarkers can be divided into different groups: protein-based, DNA-based, lipid/ 
metabolites-based and RNA-based markers. Proteomics techniques (e.g., mass 
spectrometry, electrophoresis, chromatography, and enzyme-linked immunosorbent 
assays (ELISA)) are most routinely used to identify protein-based biomarkers and to 
validate their usefulness, while genomics techniques (e.g., oligonucleotide microarray, 
RT-PCR, and next-generation sequencing) are used for the identification and validation 
of DNA and RNA-based biomarkers.  
1.3.3. Protein-based biomarkers 
Among the protein markers used for detecting PCa, PSA is the first fully accepted and 
approved biomarker that has been commercially used in clinics since the early 1990s. 
Furthermore, prostatic acid phosphatase (PAP), alpha-methyl Co-A racemase 
(AMACR), prostate-specific membrane antigen (PSMA), prostate stem cell antigen 
(PSCA), early PCa antigen (EPCA), and human kallikrein 2 (KLK2) are examples of 
additional, protein-based biomarkers that are used in PCa research.  
1.3.4. DNA-based biomarkers 
Genetic alterations: Several hereditary and sporadic genomic alterations (including 
mutations, chromosomal arrangements, gene deletion, gene amplification, etc.) have 
been reported in PCa. Table 3 shows a list of known gene alterations in PCa.  
Table 3. Examples of DNA-based PCa biomarkers 
Gene Function Alteration in 
PCa 
CHEK2 Involved in DNA damage signaling pathway, upstream of P53 Deletion 
NBN Involved in cell cycle check point and DNA double-strand 
break repair 
Deletion 
NKX3-1 Tumor suppressor gene Deletion 
CHD1 Adhesion molecule  Deletion 
PTEN Tumor suppressor gene  Mutation 
RB1 Tumor suppressor gene  Mutation 
MYC Transcriptional activator  Amplification 
EGFR Growth factor Amplification 





Epigenetic alterations: It has been reported that epigenetic changes occur already in the 
early stages of PCa, and at a higher frequency than genetic changes (Gaster, 2013). 
Histone modification and altered methylation are the two main epigenetic alterations that 
have been reported for PCa. DNA methylation is catalyzed by DNA methyltransferase 
enzyme that includes the addition of a methyl group to the 5´-carbon of cytosine in CpG 
sequences. The majority of CpGs in the human genome are methylated, whereas most 
of the CpG islands (small clusters of CpGs that are found in the 5´region close to the 
promoter of the genes) remain unmethylated which contributes to these regions being 
transcriptionally active (facilitating the binding of transcription factors and co-factors). 
Alteration in DNA methylation is one of the earliest events in tumorigenesis. DNA 
methylation in promoter regions represses the transcription of these genes, and it is also 
considered to be a defense mechanism against mobile genetic elements. One of the most 
common and well-studied epigenetic alterations in PCa is the hypermethylation of tumor 
suppressor genes and genes involved in other pathways. Hypomethylation (global and 
gene-specific) has also been shown to be involved in human PCa progression. A list of 
the genes affected by altered DNA methylation in PCa is shown in Table 4.  
Table 4. Examples of epigenetic alterations in PCa 
Gene symbol  Pathway Epigenetic 
alteration 
CDKN2A, CCND2 Cell cycle control 
DNA 
hypermethylation 
GSTP1, MGMT DNA damage repair 
RARβ,ENDRB, CDKN1C, TIMP2 Tumor suppression 
AR, ESR1, ESR2, ERα, ERβ, RARRES1 Hormone regulation 
uPA, HPSE Tumor invasion and metastasis DNA 
hypomethylation CAGE Cellular proliferation 
 
GSTP1 gene encodes an enzyme which is involved in detoxification and protection of 
DNA from oxidants and carcinogens. Hypermethylation of GSTP1 has been reported in 
more than 90% of PCa and about 70% of PIN lesions (Nakayama et al., 2004). It has 
been reported that detection of GSTP1 methylation in urine sediments collected after 
prostatic massage results in 75% sensitivity and 98% specificity for PCa detection 
(Woodson et al., 2008). In that study, GSTP1 methylation was more frequently detected 
in urine samples of patients with a higher tumor volume and later stage disease. 
Detection of GSTP1 methylation in 20% of men with prediagnostic PSA less than 4 
ng/ml and in 90% of the men with prediagnostic PSA more than 4 ng/ml PSA has also 
been reported (Woodson et al., 2008). Histone modifications including methylation, 
phosphorylation, acetylation, and deacetylation are other types of epigenetic alterations 
that regulate gene expression in PCa. CAR, CPA3, and RARB are some examples of 
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genes, which are suppressed or downregulated in PCa by histone deacetylation (Roobol 
et al., 2013; Belbase et al., 2013; Miocinovic et al., 2013).  
Histone methylation is an emerging area of research particularly in PCa, but it cannot be 
outlined in great detail here. Nevertheless, some epigenetic modifiers, e.g, LSD1 and 
EZH2 have been specifically associated with the progression of PCa and development 
of CRPC. For example, the Histone demethylase LSD1 (KDM1A) is also thought to play 
a role in prostate and other cancers, as poor patient outcome has been correlated with an 
increased expression of this gene.  Therefore, the inhibition of KDM1A and, potentially, 
of other epigenetic factors has attracted much attention as a possible treatment for cancer. 
1.3.5. RNA-based biomarkers 
The development of new transcriptome technologies, such as microarrays and next-
generation sequencing, have resulted in growing interest in the field of RNA biomarkers. 
RNA-based biomarkers are also interesting due to the fact that they reflect the functional 
state and the state of the biological systems of the cells. Moreover, RNA expression 
levels integrate both the genetic and epigenetic regulation mechanisms of these genes. 
Among different kinds of RNAs, micro RNA (miRNA), long non-coding RNA (ln-
RNA), and mRNA are currently extensively studied in PCa.  
1.3.5.1. miRNAs in PCa 
miRNAs are short (approximately 17-25 nucleotides long) non-coding RNAs that form 
1- 3 percent of the mammalian genome (Vasarainen et al., 2013). miRNAs play a key 
role in the regulation of gene expression at the post-transcriptional level. They perform 
this role by either translation repression or mRNA degradation (Carter, 2013; Baum, 
2013; Gulati and Etzioni, 2013). It has been reported that some of the miRNA function 
essentially like tumor suppressors (i.e., suppressing the activity of oncogenic genes and 
proteins), while others have oncogene-like action (Kobayashi et al., 2013; Zuzana et al., 
2013; Altarac, 2013; 2013; Simmons, 2013; Salomon, 2013; De Coninck, Braeckman 
and Michielsen, 2013). Furthermore, it has been shown that the expression levels of most 
miRNAs are tissue-specific (Makovey, Stephenson and Haywood, 2013). The 
expression of miRNAs is frequently altered during cancer development and metastasis, 
and miRNAs, therefore, can be used as diagnostic or prognostic markers. The stability 
of miRNAs in the blood stream makes circulating miRNAs a useful target, particularly 
suitable for less invasive biomarker studies based on blood or urine (Xiao et al., 2014; 
Lee and Jung, 2013). Different molecular technologies (e.g., microarrays, quantitative 
RT-PCR, and deep sequencing) have been used for miRNA profiling. Several studies 
have discovered different miRNAs in association with PCa as diagnosis markers 
(miRNA-107, miRNA 141, and miRNA93) (Kilpelainen et al., 2013; Melnikow et al., 
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2013; Howard, 2013), prognosis (miRNA-200b, miRNA-375 and miRNA451) 
(Sammon, Sukumar and Trinh, 2013; Melnikow et al., 2013) and predictive markers 
(miRNA-21) (Lippi, Mattiuzzi and Cervellin, 2013). 
1.3.5.2. Long non-coding RNAs in PCa 
Another group of non-coding RNAs are long non-coding RNAs. Their length varies from 
200 bases up to 100kb. lnRNAs have much lower expression level in comparison with 
mRNA and they do not encode any protein but instead they have regulatory feature 
(Wang et al., 2013). lnRNAs are divided into two different groups on the basis of their 
genomic localization: intergenic lnRNAs and intronic lnRNAs. PCA3 is the most well-
known and clinically relevant lnRNA-based biomarker for PCa. An overexpression of 
PCA3 has been reported in over 95% of PCa cases (Howard et al., 2013). Urine-based 
PCA3 tests are now commercially available and have been reported to provide higher 
specificity in comparison to PSA (Shaw, Scott and Ferrante, 2013; Howard et al., 2013). 
In one of the most promising studies in this field, conducted by Prensner et al., the 
authors found 121 new PCa-associated lnRNAs (Ilic et al., 2013). Most interestingly, 
PCa-associated non-coding RNA transcripts-1 (PCAT-1) showed very significant 
overexpression in high-grade organ-confined and metastasized PCa. Furthermore, PCa 
non-coding RNA-1 (PRNCR1) has been reported to be upregulated in aggressive PCa 
(Chowdhury et al., 2013). 
1.3.5.3. mRNA transcripts as PCa biomarkers 
As different cellular pathways (e.g., differentiation, survival, etc.) are reflected by altered 
gene expression patterns, mRNA transcripts are suitable targets for therapeutic and 
diagnostic cancer research. Several techniques have been developed for gene expression 
studies, e.g., northern blotting, RNase protection assay, in situ hybridization, RT-PCR 
combined with DNA sequencing, and microarrays (Parker and Barnes, 1999; Hod, 1992; 
Saccomanno et al., 1992; Weis et al., 1992; Bucher, 1999). During the last few years, 
dramatic improvements in the available methods and the development of new high-tech 
methods, such as microarray and next-generation sequencing, have made the whole-
genome expression studies possible. This has had a fundamental impact on different 
fields of cancer research, e.g., molecular diagnostics, tumor development and 
progression pathway classification, novel drug target identification, as well as drug 
discovery and development. Microarray-based gene expression profiling, quantitative 
RT-PCR and, more recently, novel DNA and RNA sequencing methods are now 
commonly used to identify novel biomarkers in cancer diagnostics and a brief summary 
of them is given below.  
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1.4. Microarray and gene expression profiling 
The microarray technique was developed in parallel by Lipshutz et al. (Lipshutz et al., 
1999), and Schena in the laboratory of Patrick Brown (Schena, 1995). DNA microarrays 
provide the unique possibility to study and monitor the expression levels of thousands 
of genes in a quantitative, rapid and reproducible manner. Spotted array and high-density 
oligonucleotide array are still the two most widely available basic types of array 
technologies. The microarray technology is now rapidly being replaced by next-
generation DNA sequencing technologies, although both technologies are likely to co-
exist for some time to come.  
Spotted microarrays were initially manufactured by using xyz robots to spot pre-
synthesized oligonucleotides (PCR products, cDNA) on specially coated glass slides 
(Schena et al., 1995). Sequences to be printed are chosen from well-characterized genes 
and public databases of expressed sequence tag (EST). About 80,000 spots can be fitted 
onto the surface of a slide. The possibility of concurrent analysis of two different samples 
provides the advantage of testing a control sample that is related to the experimental 
sample. This could also be considered as a disadvantage for this technology because it 
only provides a relative estimation between two samples (Macgregor and Squire, 2002).  
Oligonucleotide arrays were pioneered by the US-based company Affymetrix. 
Photolithography is used to generate thousands of in situ synthesized oligomers onto 
glass slides called GeneChipsTM (Fodor et al., 1991). In the latest versions of Affymetrix 
arrays, 10-20 different oligonucleotide probes for each gene are specifically designed 
from the 3´ end of the transcript. Approximately 500,000 probes can be deposited onto 
a single GeneChipTM and over 40,000 genes and ESTs can be analyzed by one chip. The 
ability to measure the absolute gene expression levels in many samples is the main 
advantage of this technique (Macgregor and Squire, 2002), and it also provides the 
subsequent bioinformatics analysis with assay speed and standardized methodology.  
Since the early 2000s, microarray-based gene expression profiling has been used to 
measure the expression of thousands of genes in parallel and across many different 
biological samples, allowing researchers to compare their expression levels with each 
other. Numerous larger-scale microarray studies have used gene expression profiling to 
identify novel genes that could have potential as PCa diagnostic tools and prognosis 
markers (Dhanasekaran et al., 2001; Magee et al., 2001; Welsh et al., 2001; Luo et al., 
2001; Stamey et al., 2001; Luo et al., 2002a; Singh et al., 2002; Rhodes et al., 2002; 
Varambally et al., 2002; Henshall et al., 2003; Glinsky et al., 2003) as well as predictive 
markers (Latil et al., 2003; Glinsky et al., 2004; Schlicht et al., 2004; Li et al., 2005; 
Sooriakumaran et al., 2009). Since the development of fast DNA sequencing methods 
(since 2010), the use of microarrays has been gradually declining, but the vast amount 
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of data generated and deposited in open access, public data repositories along with the 
published reports will continue to provide a very useful base for biomarker identification.  
1.5. DNA and RNA sequencing 
The initial sequencing and analysis of the human genome by using conventional Sanger 
sequencing technology took about 13 years (de Jong et al., 2001). In contrast, the next-
generation sequencing (NGS) technologies which have revolutionized the genomic 
research have reduced the required time to a single day. Nowadays, a panel of different 
NGS technologies, based on different technology platforms, have been developed for the 
parallel sequencing of millions of small fragments of DNA (“deep sequencing”). The 
term second-generation sequencing is used to describe an older PCR-based sequencing 
method in contrast to the amplification-free, third-generation techniques that can 
sequence a single molecule (Schadt, Turner and Kasarskis, 2011). The application of 
these advanced sequencing technologies makes it possible to discover genetic and 
epigenetic changes possibly responsible for functioning in the development and 
progression of cancer. In comparison to microarray technologies, RNA/DNA 
sequencing by NGS methods is cheaper and provides enhanced resolution, higher 
dynamic range, and better reproducibility. NGS methods also make it possible to identify 
mutations and novel transcriptomes, such as non-coding RNAs, splice variants, and 
fusion genes, which were not detectable with microarray technology.  
1.6. Real-time PCR methods 
The principles for polymerase chain reaction (PCR) were developed by Karry Mullis 
(Mullis et al., 1986). PCR allows the exponential amplification of any DNA molecules 
of suitable length. In quantitative PCR, this is further combined with the incorporation 
of fluorescent dyes or the use of fluorescently labeled DNA probes. The detected amount 
of fluorescence correlates with the original number of DNA sequences which serve as 
templates for DNA amplification. The kinetics of DNA amplification and the 
accumulation of amplified target gene fragments allow the quantitative determination of 
specific gene products in real-time. Coupling the reverse transcription technique with 
subsequent PCR enables the amplification and detection of RNA molecules (Rappolee 
et al., 1988). Several advantages, e.g., a homogenous assay avoiding post-amplification 
processing, a wider dynamic range, and quantification possibility, have made RT-PCR 
one of the most widely used methods in gene expression studies.  Real-time PCR is a 
relatively complex assay and numerous factors can affect the sensitivity, specificity, and 
reproducibility of the assay. Some of these factors are discussed below. 
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1.6.1. Different quantification strategies 
The quantification of RT-PCR data can be based on two different principles: relative and 
absolute quantification. In relative quantification, the target gene expression alteration is 
calculated in relation to a group of untreated control samples or samples from different 
time courses. In absolute quantification, the absolute copy number of the transcript is 
calculated on the basisi of a dilution series of known concentrations in which the target 
gene is used as a reference to generate a quantitative standard curve. These standard 
curves rely on a linear relationship between the threshold cycle of an unknown sample 
and the initial amount of RNA or cDNA in the sample. By comparing the DNA 
amplification in the experimental sample to the standard curve, the concentration of 
DNA in the sample can be precisely calculated.  
1.6.2. Normalization of RT-PCR 
Normalization is very important in RT-PCR in adjusting sample-to-sample variation and 
evaluating the presence of any inhibitors in the reaction mixture; it is used as a means to 
avoid or exclude false negative results. Different strategies can be used to minimize and 
correct these errors. The total RNA concentration can be used to normalize the measured 
expression level of the target gene, but this method suffers from several limitations: First, 
the level of RNA can be affected by different cellular processes. Secondly, extraction 
and reverse transcription efficiency and the quality of RNA may seriously affect the final 
outcome. A frequently used approach to avoid these limitations is to normalize the RT-
PCR results against a stably expressed control gene that could also be used as a positive 
control. Housekeeping genes (e.g. GAPDH and β-actin) are generally assumed to show 
stable and constant expression levels across all of the cells or tissues examined, and have 
been widely used as controls in gene expression assays. However, frequent observations 
of significant alterations in the expression of housekeeping genes in various stages of 
different diseases have raised serious questions about the reliability of this method (Li 
and Shen, 2013). Few studies have attempted to investigate the application of tumor 
specific genes for normalization of gene expression measurements in tumor tissues. 
HPRT has been reported as a suitable gene for normalization purposes for cancer 
research (de Kok et al., 2005). Another reliable alternative approach is to add, already 
during the RNA extraction, a known amount of artificially synthesized RNA as a 
reference gene. The spiking of RNA samples with a known concentration of an artificial 
RNA can be used to normalize the errors that occur during extraction and reverse 
transcription (Nurmi, Lilja and Ylikoski, 2000a; Huggett et al., 2005). However, this 
approach does not provide normalization for changes taking place in RNA samples 
before extraction, e.g., during sample collection and storage. But, it still represents a 
more reliable approach for the absolute quantification of RNA expression.  
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1.6.3. Detection chemistries 
Nowadays, there are several different techniques for the detection of amplified products. 
Fluorescent dyes have been widely used in different detection techniques. Using 
fluorescent dyes (e.g., SYBR Green) that bind specifically to double-stranded DNA 
(dsDNA) is the simplest method (Morrison, Weis and Wittwer, 1998), and it is the most 
widely used. The intensity of fluorescence increases proportionally to the dsDNA 
concentration. The disadvantages of this method are that the method does not allow 
multiplexing (the co-amplification and distinction of several DNA molecules in the same 
reaction), and it produces a high rate of false positive results due to the unspecific 
binding of fluorescent dyes to any dsDNA (Wittwer et al., 1997a; Simpson et al., 2000). 
Hybridization probe (Wittwer et al., 1997b), hydrolysis probe (Gibson, Heid and 
Williams, 1996; Clegg, 1992), molecular beacons (Tyagi and Kramer, 1996), and 
scorpions (Whitcombe et al., 1999) are other detection chemistries that have been used 
in RT-PCR. They all rely on the principle of fluorescence resonance energy transfer 
(FRET). Conventional short-lifetime fluorophores are used to label the probes. In some 
of these techniques, a “dark” non-fluorescent chromophore called a quencher is used to 
scatter the received energy from the fluorophore as heat, when it is in a close proximity 
to it. Although different methods, e.g., quencher dye, have been applied to reduce the 
background problem, high background and low signal-to-background ratio still remain 
major limitations in all of the previously mentioned detection techniques. Therefore, the 
autofluorescence which is inherent to all biological molecules and plastic matrices, 
combined with the high background of short-lived fluorophores may affect the 
sensitivity and reproducibility of the quantification of low-abundance targets in 
particular (Karrer et al., 1995). The application of probes bearing a label of long-lifetime 
luminescent lanthanide chelates, combined with time-resolved fluorometry (TRF) is an 
extremely suitable approach to overcome the high background observed with short-
lifetime fluorophores (Lövgren, 1990).  
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2. AIMS OF THE STUDY 
The general purpose of this study was the identification, characterization, and clinical 
validation of novel biomarkers for diagnosis and prognosis of PCa by using gene 
expression. 
The specific aims included: 
I.  To develop and optimize a highly sensitive reporting chemistry to be used for the 
development of truly quantitative and internally standardized qRT-PCR assays, 
and the comparison of CTCs in blood samples with those in prostate tissue 
samples to find a suitable sample matrix for our gene expression studies. 
II.  To examine the diagnostic potency of AMACR and AR mRNA expression levels 
in PCa detection with novel qRT-PCR assays. To investigate whether the the 
candidate biomarkers are present and informative in histologically benign tissues 
of the cancerous prostates.   
III.  The identification and validation of novel biomarkers for PCa, using 
bioinformatics data mining of large-scale, public gene expression datasets, and 
clinical biomarker validation by qRT-PCR; and the functional evaluation of 
candidate genes using siRNA technique in 2D and 3D culture models. 
IV.  To evaluate the diagnostic power of the 11 RNA biomarkers (ACSM1, AMACR, 
CACNA1D, DLX1, PCA3, PLA2G7, RHOU, SPINK1, SPON2, TMPRSS2-ERG, 
and TDRD1) in biopsy cores obtained from apparently benign areas targeted by 
magnetic resonance imaging (MRI) from men with a clinical suspicion of PCa. 
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3. SUMMARY OF MATERIALS AND METHODS 
A more detailed description of the materials and methods used in this study is available 
in the original publications (I-IV). 
3.1. Clinical samples 
Six different sample cohorts were used in this study. A written informed consent was 
obtained from all participants. The study protocol was approved by the local Ethics 
committee and it was in accordance with the Helsinki Declaration of 1975 that was 
revised in 1996. The summary of tissue and blood sample cohorts used in this study is 
presented in Table 5 and more details about each cohort are represented in chapters 3.1.1 
- 3.1.6. 





Sample matrix Number of 
samples  
Publication 
TYKS Men with PCa Blood 12 I 
DBUT Healthy male and 
female 
Blood 5 I 
TYKS Men with 
localized PCa 
Tissue from RP 
specimens 
138 I, II 
TYKS Men with 
localized PCa 
Tissue from RP 
specimens 
178 III 
TYKS Men with 
localized PCa 
Cross sections from RP 
specimens 
3 III 
SUH Men with bladder 
cancer 
Tissue from CP 
specimens 
19 II, III 
TYKS Men with clinical 
suspicion of PCa 
MRI-targeted biopsy 99 IV 
TYKS: Turku University Hospital, Turku, Finland; DBUT: Division of Biotechnology, 
University of Turku, Turku, Finland; SUH: Skåne University Hospital, Malmö, Sweden. 
3.1.1. Prostate tissues from patients with PCa (Cohort A) (I,II) 
Prostate tissue samples were collected from 79 patients operated by radical 
prostatectomy (RP) because of clinically localized PCa at Turku University Hospital, 
Turku, Finland (TYKS). From each fresh prostatectomy specimen two small samples 
were taken immediately after surgery, one from the suspected cancerous area, the other 
from an adjacent, suspected benign area. Half of each tissue sample was sent to 
experienced pathologists at TYKS for histopathological examination, while the other 
half was stored in guanidine isothiocyanate buffer (GITC buffer, containing 4 mol/L 
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guanidine thiocyanate, 25 mmol/L sodium citrate dehydrate, 0.5% W/V sodium lauryl 
sarcosinate, and 0.7% V/V 2-mercaptoethanol) and stored at -80 ˚C until further 
processing. On the basis of histopathological examination results for some patients both 
samples had been taken from either benign or cancerous areas. For 59 prostates both 
samples were examined; in 9 and 11 cases (cancerous or benign, respectively), only one 
sample per prostate was examined. In total, 69 RP-Be samples and 69 RP-PCa samples 
were examined.   
3.1.2. Prostate tissues from patients with PCa (Cohort B) (III) 
Due to running out of cDNA from first RP tissue sample cohort, another tissue sample 
cohort was processed. 180 prostate tissue samples were collected from 90 PCa patients, 
operated by radical prostatectomy (RP) in (TYKS) between 2004 and 2007. The samples 
were collected, examined, and stored as described for cohort A. Because of a technical 
problem during RNA extraction, two samples were excluded, which resulted in 178 
samples (104 RP-Be samples and 74 RP-PCa samples) for further analysis.  
3.1.3. Prostate tissue from cross-section of PCa patients (II) 
Single cross-sections of the prostate were collected from three men with PCa who had 
undergone RP at TYKS. A 2 mm horizontal mid-plane tissue slice covering the entire 
gland was obtained from each prostate. Prostate slices were fixed on a Styrofoam plate 
with grid guide on it and cut into 5x5 mm pieces. This resulted in 44-62 pieces depending 
on the size of the prostate. The samples were stored in RNAlater (Qiagen, Germany) at 
-20 ˚C until RNA extraction. A tissue section from adjacent inferior and superior sides 
of the slice used for mRNA measurements was fixed in formalin and embedded in macro 
paraffin blocks (FFPE) for histological examination. The histology of the tissue samples 
collected for mRNA experiments was determined by matching each sample with the 
corresponding area on sections used for histological examination. For 
immunohistochemistry experiments macrosections of 5 µm in thickness were cut from 
the FFPE blocks of each prostate, next to the HE-stained sections. 
3.1.4. Prostate tissues from men with bladder cancer (II, III) 
Prostate tissue samples were collected from 19 men who had bladder cancer, and who 
underwent cyctoprostatectomy at Skåne University Hospital in Malmö, Sweden. One 
tissue sample was collected from each specimen and samples were stored fresh frozen 
at -80 ˚C until RNA extraction. The specimens were further examined histologically by 
a pathologist. The results revealed that seven glands were tumor-free, while the other 12 
contained an incidental tumor but the mRNA experiment samples had been collected 
from a tumor-free area.  
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3.1.5. Prostate tissue biopsies from men with clinical suspicion of PCa (IV) 
Prostate tissue biopsies were collected from 100 men with a clinical suspicion of PCa 
(PSA 2.5-20 ng/ml and/or abnormal DRE). Patients underwent magnetic resonance 
imaging (MRI) at 3 teslas before biopsy. A total number of 6+6 biopsies were 
systematically collected from each patient. In the case of a suspected lesion in the MRI, 
two cognitively targeted biopsies were collected from the index lesions. Finally, two 
fresh biopsies were obtained for biomarker research. These biopsies were obtained from 
the peripheral zone of the prostate without clinical or radiological evidence of tumor. 
Tissue sample cores were placed in RNA-stabilizing solution (RNAlater, Ambion, 
Austin, TX, USA) and stored at -80 °C until RNA extraction.  
3.1.6. Blood samples from PCa patients and healthy individuals (I) 
Blood samples were taken from 12 prostate cancer (PCa) patients with metastasized PCa 
at TYKS, and from 3 healthy males and 2 healthy females at the University of Turku 
Division of Biotechnology. From each individual, 2.5 mL of blood were collected in 
PAXgene blood RNA tubes (PreAnalytix, Germany) and stored at -20 °C until further 
processing.  
3.2. RNA extraction and reverse transcription 
PAXgene Blood RNA kit (PreAnalytix, Germany) was used for the extraction of total 
RNA from blood samples. According to the manufacturer’s instructions, the samples 
were first incubated for 24 h at room temperature. For the extraction of total RNA from 
tissue samples, RNeasy mini kit (Qiagen, Germany) was used according to 
manufacturer’s instructions. A known and fixed amount of artificial mmPSA mRNA (in 
vitro mutated form of PSA) (Nurmi et al., 2000a) was added as internal standard during 
the extraction procedure after cell lysis. To degrade and remove the genomic DNA 
contaminants an additional DNase I (Qiagen) treatment step was performed according 
to manufacturer’s instructions. 
The quality of the extracted RNA was characterized by gel electrophoresis and the RNA 
concentration was measured using Nanodrop (Thermo, USA) spectrophotometer. The 
extracted RNA was reverse-transcribed to cDNA by using High Capacity cDNA Archive 
Kit (Applied BiosystemsUSA) following the manufacturer’s instructions. The cDNAs 
were stored at -20 °C.  
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3.3. Internal and external RNA standards (I, II, III, IV) 
A fixed and known amount (106 molecules to each tissue or blood sample) of a synthetic 
mutant form of wild-type KLK3gene (which encodes for PSA protein) RNA was used as 
internal standard to facilitate monitoring the loss of RNA during extraction and reverse 
transcription processes. The mutant mmPSA form contains, in comparison to the wild-
type, an inversion and deletion. A control representing the maximum yield of internal 
standard RNA was prepared by the reverse transcription of the same amount of standard 
RNA as was added to each sample.  
For each mRNA target a dilution series of purified PCR products was used as a template 
for the construction of a standard curve for the quantitative measurements. End-point 
PCR assays and gel electrophoresis were used to produce and detect the target gene. The 
PCR products and the target DNA were purified from agarose gel. The purified PCR 
product concentration was measured by using Picogreen reagent kit (Invitrogen, USA) 
and was diluted to different concentrations. 
3.4. Real-time PCR 
Two different real-time detection principles of PCR amplification products were used in 
this study. The applicability of a new detection method for PCR amplification products, 
called lanthanide chelate complementation (LCC) was compared with a previously 
published detection method based on hydrolysis enhanced luminescent chelate (HELC) 
chemistry. In both methods lanthanide chelates were used for probe labeling, and time-
resolved fluorometry (TRF) was used for the detection of fluorescence emission (Figure 
2). 
To investigate the applicability of the new LCC reporting chemistry for real-time qRT–
PCR and to compare its performance with HELC chemistry as a reference method, two 
different assays were developed for KLK3 gene. 
Specific real-time PCR assays based on HELC detection chemistry were designed and 
developed for target genes including KLK3, AMACR, AR, ACSM1, CACNA1D, TDRD1, 
RHOU, LMNB1, DLX1, PLA2G7, and SPON2. Previously developed and described real-
time PCR assays utilizing HELC detection chemistry (Vaananen et al., 2015; Vaananen 
et al., 2013) were used for PCA3, SPINK1, TMPRSS2-ERG III, and TMPRSS2-ERG IV 
genes. 
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Figure 2. Schematic illustration of both methods for real-time detection of PCR amplification. 
(A) Assay principle of the HELC method, (B) Assay principle of LCC method. (Figure from 
original publication I.) 
3.4.1. Reagents and temperature profile conditions 
Oligonucleotide primers and probe sequences are shown in Table 6. Quencher probes 
were purchased from Thermo (USA) and labeled with either QSY-7 or Dabcyl at the 3’ 
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end. Reporter probes with the amino linker C6 modification at the 5′ end of HELC 
probes, lanthanide carriers for LCC probes, and LCC antenna probes with a C2 amino-
modification at the 3´ end (enabling labeling) were also ordered from Thermo (USA). 
Reporter probe labeling was performed in-house following a previously described 
procedure (Nurmi et al., 2000b). Another previously reported procedure was also applied 
to the labeling of the lanthanide carrier and antenna probe for the LCC probes (Karhunen 
et al., 2010). 
Each PCR was performed in a total volume of 25 µl containing 2.5 µl of cDNA template 
or DNA standard. Instead of DNA template, 2.5 µl of DMPC-treated H2O were used for 
negative control PCR reactions. PCR reactions were performed on a 96-well plate (Hard-
shell PCR plate BLK/WHT, Bio-Rad or ABgene Thermo-Fast 96 Robotic plate white). 
PCR amplifications were performed in a PTC-200 MJ Research Thermal Cycler (MJ 
Research, USA). A thermal profile consisting of a 15 s denaturation at 95 ˚C, followed 
by 1 min of annealing and extension at 64 ˚C was used for both HELC and LCC probes. 
A higher annealing and extension temperature was used during the first 10 cycles of 
amplification to improve the specificity of the assays. The annealing and extension 
temperature was decreased to 62 ˚C after 10 cycles, and the procedure was continued for 
5 more cycles. Further amplification followed, with 30 cycles of 15 s denaturation at 95 
˚C, and annealing and elongation for 1 min at 62 ˚C. The TRF measurement was 
performed for the HELC method at the end of every other annealing/elongation step, 
starting from cycle 15. To avoid having an extra amplification step due to raising the 
temperature from the measurement point to the denaturation point, TRF measurement 
was carried out in the LCC probe-based assay at the end of every other denaturation step, 
starting from cycle 15. The measurement temperature for both methods was 35 ˚C; 15 s 
after achieving this temperature, the thermal cycler was paused and fluorescence signals 
of all reactions were recorded by a fluorometer (Victor 1420 multilabel counter, 
PerkinElmer Life Sciences, Finland). Additional 10-minute incubation at 95 ̊ C was used 
at the beginning for enzyme activation when AmpliTaq Gold DNA polymerase was 
used. 
3.5. Immunohistochemistry (II) 
To determine the AMACR protein expression, macrosections of 5 µm in thickness were 
cut from the FFPE (formalin-fixed, paraffin-embedded) blocks of each prostate cross-
section (study II), next to the HE-stained sections. Sections were stained with a rabbit 
monoclonal AMACR (P504S) antibody (1:200, clone 13H4, Zeta Corporation). The 
detection of primary antibody was performed with EnVision+ Dual Link System-HRP 
(Dako) and visualized with DAB+ chromogen solution (Dako). The slides were observed 
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by an experienced uropathologist using a Leica DM3000 light microscope equipped with 
Leica DFC 420 digital camera and Leica Application Suite version 2.5.0 R1 (Leica 
Microsystems, Wetzlar). 
Table 6. The oligonucleotides used in RT-PCR assays in this doctoral study. 
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3.6. Gene knock-down using RNA interference 
PC3 and VCaP prostate cancer cells were used for small interfering RNA (siRNA) 
studies and other functional studies for 8 of the target genes (ACSM1, TDRD1, PLA2G7, 
SPON2, DLX1, CACNA1D, RHOU, and LMNB1). Cells were grown in RPMI-1640 at 
37˚C in standard cell culture conditions (95% humidity and 5% CO2). For siRNA studies 
31 different siRNAs (three different siRNAs for ACSM1 and four different siRNAs for 
each of the other seven genes) were ordered from Qiagen (Germany). To achieve the 
most efficient knock-down for each gene, siRNAs were tested individually and in a 
pooled mixture. First, siRNAs were plated onto plates, followed by the addition of 
Hiperfect transfection reagent (Qiagen, Germany) in Opti-MEM medium (Invitrogen, 
USA). After 15 minutes of incubation at room temperature an appropriate number of the 
cells were added into each well. ALLStars Hs cell death control siRNA (Qiagen, 
Germany) was used as positive control for the efficacy of siRNA transfection and 
ALLStars negative control (Scrambled siRNA, Qiagen, Germany) was used as negative 
control. 
3.7. Cell migration and invasion assay (wound healing) 
PC3 transfected cells were plated on 96-well plates and 72 hours after transfection, when 
cells reached the confluency, a fixed-width wound was scratched with the Woundmaker 
device (Essen Bioscience, USA).The closure of the wound was quantified and monitored 
for 72 hours with IncuCyte live-cell imager (Essen bioscience, USA). 
3.8. 3D cell culture and image acquisition for morphological analyses 
PC3 cells transfected with siRNA were detached from monolayer cultures 72 hours after 
the transfection. Transfected cells were sandwiched between two layers of Matrigel on 
uncoated Angiogenesis slides (Ibidi GmbH, Germany). Calcein AM live cell dye was 
used to stain the resulting tumor organoid cells 10 days after transferring them to the 3D 
culture medium. 
3.9. Data analyses 
To determine the threshold cycle (Ct) for each reaction of real-time PCR, a graph was 
plotted by using signal-to-background ratio against the cycle number. The Ct values were 
determined visually as the cycle number where the fluorescence level crossed the 
threshold line and differed significantly from background level. For each concertation of 
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external DNA standard the difference between the Ct value of the target gene and the Ct 
value of the reaction containing the maximum yield of internal standard RNA (∆Ct) was 
calculated. Standard plots were constructed for each target mRNA by plotting ∆Ct values 
against the ten-based logarithm of the external standard concentration. For each 
unknown sample reaction, ∆Ct value was calculated and applied to determine the copy 
numbers using the standard plot. The obtained copy numbers were normalized to sample 
size using total RNA amount. After normalization the target mRNA expression level was 
reported as mRNA copies per µg of total RNA. 
Samples were analyzed in triplicates and considered as positive only when all three 
replicates were positive. 
3.10. Statistical analyses 
Statistical analyses were performed with SPSS 20.0 (IBM). Nonparametric tests were 
used to examine the association between clinicopathological parameters and target 
mRNA expression levels.  
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4. RESULTS AND DISCUSSION 
This doctoral work has mainly focused on evaluating the potency of the mRNA 
expression of 13 candidate genes as biomarker for PCa diagnosis and prognosis. To be 
able to choose the most sensitive and specific method for mRNA expression studies by 
RT-PCR, the applicability of two different labeling chemistries developed on the basis 
of time-resolved fluorometry (TRF) were assessed.  
4.1. Lanthanide chelates and TRF in RT-PCR (I) 
The usefulness of gene expression studies by means of microarray and quantitative RT-
PCR for cancer classification, and their application in the identification of biomarkers to 
improve the diagnosis and prognosis of cancer has been reported in numerous studies 
(Clark-Langone et al., 2007; Scott et al., 2011).  Quantitative RT-PCR is known as the 
gold standard method for quantifying gene expression, and it offers several advantages, 
such as, high sensitivity, specificity, and reproducibility, as well as accurate quantitation 
over a wide dynamic range. 
Fluorescent-labeled probes designed on the basis of fluorescence resonance energy 
transfer (FRET) are the most common method used in the detection of PCR products. 
High background, which is the result of using conventional short-lifetime fluorophores 
for the labeling of the probes, and autofluorescence from biological sample matrices and 
the plastic materials of reaction vessels, affects the sensitivity and specificity of RT-PCR 
assays. Using long-lived luminescent lanthanide chelate probes with time-resolved 
fluorometry (TRF) has been suggested to overcome this limitation. 
In this doctoral work, the applicability of a new reporting chemistry, lanthanide chelate 
complementation (LCC), in real-time qRT–PCR was investigated and its performance 
was compared with a previously described hydrolysis enhanced luminescent chelate 
(HELC) chemistry as a reference method. 
The methods were evaluated by measuring the expression level of KLK3 gene (as model 
analyte) in prostate tissue and peripheral blood samples taken from cancerous patients 
and healthy controls. A specific assay based on the LCC method was developed and 
optimized for measuring KLK3, and assay performance was compared with a previously 
developed KLK3 assay based on the HELC method. After the optimization of the assays, 
the same limit of detection was achieved for KLK3 in standard series (1 copy/µl 
template) for both assays (Figure 3). The expression level of KLK3 was measured in 
three different cDNA dilutions (1:100, 1:1000, and 1:10,000) of 20 tissue samples 
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collected from 10 PCa patients to investigate the effect of the amount of template cDNA 
on assay performance. 
KLK3 measurement in blood and tissue samples resulted in identical classification in the 
positive and negative results with both methods. The expression of KLK3 was detected 
in all tissue samples with both methods. According to Deming regression analysis 
results, there was significant correlation for KLK3 expression between 1:100 and 1:1000 
dilutions. However, there was a significant difference in the KLK3 expression levels for 
the 1:10,000 dilution between the two detection methods. 
 
Figure 3. Amplification curve of KLK3 (PSA) standard dilution series (1–106 copies of purified 
PCR products) and no template control (NTC) with both methods 
For mimicking the patient blood samples and CTCs, female blood samples were spiked 
with different numbers of LNCaP cells. KLK3 level was measured with both methods. 
The same limit of detection for the spiked blood samples with LNCaP cells (5 LNCaP 
cells in 2.5 ml of blood) was obtained with both methods. The expression of KLK3 was 
detected only in one similar patient’s blood sample with both methods. This could be 
explained by spiked blood sample results, and the possibility of the number of CTCs in 
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4.2. Expression of AMACR and AR in cancerous and noncancerous 
prostate (II) 
In this study, the expression of AMACR, AR, and KLK3 was measured in 138 prostate 
tissues obtained from 79 men with clinical PCa who had undergone radical 
prostatectomy, and in 19 Cystoprostatectomy (CP) samples obtained from 19 men with 
bladder cancer but without clinical PCa. To determine the detailed areas of altered 
AMACR expression, the AMACR mRNA and protein levels were examined by qRT-
PCR and immunohistochemistry, respectively, in whole prostate cross-sections obtained 
from three RP specimens.  
4.2.1. Overexpression of AMACR 
An overexpression of AMACR in PCa and a low to undetectable expression of AMACR 
in normal tissues was reported in 2000 (Xu et al., 2000). AMACR staining using a rabbit 
monoclonal antibody was reported as a new molecular marker for prostate carcinoma in 
2001 (Jiang et al., 2001). In our study, the expression of AMACR was detected in all of 
the 138 RP samples and there was no statistically significant difference between 
histologically benign and cancerous samples. The expression of AMACR was detected 
in 14/19 CP samples, and a 195-fold increase in the expression of AMACR RNA was 
observed when cancerous radical prostatectomy tissues were compared to the 19 CP 
samples (p<0.0001). The expression of AMACR was statistically significantly higher in 
samples from men with PCa of pathological stage pT3 and pT4 than in samples from 
men with PCa classified as pT2 (p=0.006), but there was no association with the Gleason 
grades. A comparison of the expression levels of AMACR RNA in histologically benign 
prostate tissues with 19 CP samples also resulted in a 126-fold overexpression 
(p<0.0001) suggesting an alteration of molecular content in areas larger than tumor foci. 
Increased biomarker expression in histologically benign tissues in itself can be caused 
by the cancer field effect (Ogden, Cowpe and Green, 1990). The field effect or field 
cancerization was first suggested by Slaughter et al. (Slaughter, Southwick and Smejkal, 
1953); nowadays it has an extended definition and is defined as any molecular 
abnormalities in tissues that appear histologically benign (Hockel and Dornhofer, 2005). 
To confirm this AMACR-related result, three prostate cross-sections obtained from three 
PCa patients were evaluated in a systematic manner to determine if samples from areas 
outside the tumor lesions could be equally informative of the presence of cancer. The 
expression of AMACR was detected in all tissue pieces from three prostate sections. 
There was a 1.9-fold overexpression in median AMACR mRNA in cancerous samples 
compared to histologically benign samples (p<0.001). This is in contrast with the result 
of the RP samples cohort, but it could be explained by considering the fact that all 
histologically benign (n=112) and cancerous samples (n=35) in the cross-section study 
Results and Discussion 
45 
have been collected from a limited number of patients (only three). AMACR staining 
and immunohistochemical analysis resulted in positive AMACR staining in 100% of 
areas that contained carcinoma on both the superior and inferior sides of cross-sections 
of prostate B and C, while on the superior side of prostate A, AMACR staining was 
observed in 96% of the carcinoma areas. Furthermore, AMACR staining was detected 
in some of the benign and PIN areas. Positive AMACR staining has been previously 
reported in 0-21% of histologically normal prostate epithelium (Luo et al., 2002b; Beach 
et al., 2002; Rubin et al., 2002). This could be explained by the use of different 
antibodies in different studies, and their sensitivity limitations.  
4.2.2. Overexpression of AR and KLK3 
Androgens drive the growth and development of the prostate gland through intracellular 
androgen receptors (AR). Gene amplification and overexpression of AR, that facilitates 
the growth and maintenance of PCa cells in a very low amount of androgens in 
castration-resistant PCa, has been reported in a number of previous studies (Koivisto et 
al., 1997; Visakorpi et al., 1995; Bubendorf, 1999). Here, we studied and compared the 
expression alteration of AR RNA in cancerous prostates (primary PCa) and in 
noncancerous prostates. 
The expression of AR and KLK3 were detected in all of the CP and RP samples. In KLK3 
expression, the gene coding for the PSA did not show any statistically significant 
differences between different groups of samples. The median RNA expression level of 
AR was 6.4 times higher in the RP-Be samples (p<0.0001) and 6.6 times higher in the 
RP-PCa samples than in CP samples. There was no statistically significant difference in 
AR expression between cancerous radical prostatectomy samples and histologically 
benign samples. There was no association for the expression of AR and KLK3 with 
Gleason grade in RP samples, but there was a statistically significant difference for the 
expression of AR and KLK3 in patients with pathological stage pT3 and pT4 PCa 
compared with pT2 PCa patients (p=0.005 and p=0.004, respectively). 
The Pearson's correlation coefficient revealed a strong correlation (r=0.86) between AR 
and AMACR expression levels when samples from all groups were combined. ROC 
curve analyses for KLK3, AR, and AMACR mRNA expression resulted in AUC values 
0.58, 0.717, and 0.923 for KLK3, AR, and AMACR mRNA levels, respectively, when 
cancerous radical prostatectomy samples were compared with CP samples. The 
comparison of histologically benign samples with CP samples also resulted in 
comparable AUC values 0.64, 0.77, and 0.89 for KLK3, AR, and AMACR mRNA levels, 
respectively (Figure 4).  
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Figure 4. ROC curve analyses for KLK3, AR, and AMACR mRNA expression. A. ROC curve 
analysis for RP-PCa and CP tissues; AUC values are 0.58, 0.717, and 0.923 for KLK3, AR, and 
AMACR mRNA levels, respectively. B. ROC curve analysis for RP-Be and CP tissues; AUC 
values are 0.64, 0.77, and 0.89 for KLK3, AR, and AMACR mRNA levels, respectively. (Figure 
from original publication II) 
The overexpression of AR mRNA in both histologically benign and cancerous prostate 
tissue samples from cancerous prostates compared to samples from prostates without 
any evidence of PCa confirms the previous study results that PCa is dependent on the 
androgen/AR signaling pathway in all stages of the disease and not only in the metastatic 
stage (Chen et al., 2004; Isaacs, 1994; Linja et al., 2004). Furthermore, on the basis of 
AMACR mRNA overexpression in histologically benign samples, and comparable AUC 
values for AMACR mRNA expression between histologically benign and cancerous 
samples, the usefulness of an AMACR mRNA measurement with a qRT-PCR assay for 
patients with false negative biopsies (i.e., lesion missed in the biopsies) in assessing their 
cancer risk could be considered. 
4.3. Identification and validation of novel biomarkers for PCa (III) 
Applying both different filtering and approaches for mining the databases in order to 
identify specific biomarkers for the stratification and discrimination of primary PCa 
either from a normal prostate or from metastasized PCa resulted in eight candidate genes 
(ACSM1, AMACR, CACNA1D, DLX1, PLA2G7, RHOU, SPON2, and TDRD1) for 
further clinical and functional validations. 
4.3.1. Evaluation of the mRNA expression of candidate genes in tissue samples 
The expression of eight selected candidate genes in addition to KLK3 was measured in 
a tissue cohort including 178 prostate tissues obtained from 90 men with clinical PCa 
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and 19 previously mentioned CP samples. Expression levels and the frequency of 
detection of target mRNAs in different groups of samples are shown in Figure 5 and 
Table 7. 
 
Figure 5. Expression levels of eight candidate biomarker genes (mRNA copies/µg of total RNA) 
and KLK3 in cystoprostatectomy samples (CP), histologically benign radical prostatectomy 
samples (RP-Be), and cancerous radical prostatectomy samples (RP-PCa). Boxes show the 
interquartile range, with the line in the middle denoting the median value and circles representing 
the outliers. (Figure from original publication III) 
Table 7. Frequency of detection of target mRNAs in different tissue samples. 











KLK3 7 (100%) 12 (100%) 104 (100%) 74 (100%) 
LMNB1 5 (71%) 12 (100%) 104 (100%) 74 (100%) 
ACSM1 7 (100%) 12 (100%) 104 (100%) 74 (100%) 
CACNA1D 7 (100%) 12 (100%) 104 (100%) 74 (100%) 
RHOU 2 (28%) 7 (58%) 104 (100%) 74 (100%) 
DLX1 0 (0%) 5 (41%) 88 (85%) 73 (99%) 
TDRD1 2 (28%) 6 (50%) 101 (97%) 72 (97%) 
PLA2G7 7 (100%) 12 (100%) 104 (100%) 74 (100%) 
SPON2 7 (100%) 12 (100%) 104 (100%) 74 (100%) 
(CP-B samples) indicates benign prostate tissue from patients without PCa, (CP-IPCa samples) 
indicates benign prostate tissue from patients with incidental PCa, (RP-B samples) indicates 
benign prostate tissue from patients with PCa, and (RP-PCa) indicates cancerous tissue from 
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The p values of the comparison of differential expression levels between different groups 
of samples and the association of mRNA expression of target genes in prostate tissue 
with major clinical and pathological parameters of PCa has been listed in Table 8.  
Table 8. Association of mRNA expression of target genes with clinicopatholocical parameters. 
(Table from original publication III) 
 Target mRNA 
 KLK3 RHOU ACSM1 CACNA1D LMNB1 TDRD1 PLA2G7 DLX1 SPON2 
CP (n=19) vs. RP-B (n=104) 0.008 <0.001 <0.001 <0.001 0.001 0.001 <0.001 0.008 <0.001 
CP (n=19) vs. RP-PCa (n=74) 0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 
RP-PCa (n=74) vs. RP-B 
(n=104) 
0.7 0.30  0.001  0.001  0.14  ˂0.001  0.804  ˂0.001  0.00  
Prostate Gleason ≥ 7 (n=43) vs. 
Prostate Gleason ≤,6 (n=43)* 
0.866 0.249 0.849 0.799 0.331 0.115 0.048 0.074 0.707 
pT 2 (n=51) vs. pT 3,4 (n=35)* 0.161 0.535 0.833 0.004 0.072 0.377 0.715 0.001 0.775 
PSA relapse (n=15) vs. No 
PSA relapse (n=65) * 
0.225 0.980 0.206 0.090 0.151 0.209 0.427 0.156 0.023 
* A single value of mRNA expression of each gene, was used (consistently from the right lobe 
the prostate) for each patient with two cancerous samples 
The comparison of all 19 cystoprostatectomy samples (CP) with either histologically 
benign (RP-B) or cancerous radical prostatectomy (RP-PCa) samples resulted in 
statistically significant p values for all the target genes, while only the expression of 
ACSM1, CACNA1D, DLX1, SPON2, and TDRD1 was capable to discriminate RP-PCa 
samples from RP-B samples. To investigate the association of mRNA expression of 
target genes in prostate tissue with major clinical and pathological parameters of PCa, 
for each patient with two cancerous samples a single value of mRNA expression of each 
gene, was used (consistently from the right lobe of the prostate). Except for PLA2G7 
(p=0.048), none of the other target genes were able to discriminate aggressive tumors 
(Gleason score ≥7) from less aggressive PCa (Gleason score <7) on their own. The 
expression of CACNA1D and DLX1 were significantly different between T2 and T3 
categories of TNM staging (p=0.004 and 0.001, respectively). Only the expression of 
SPON2 (p=0.023) was able to distinguish between patients with or without PSA relapse.  
The ROC analysis was used to evaluate the sensitivity and specificity of candidate 
biomarkers (Figure 6). A comparison of all 19 CP samples (considered as negative) with 
cancerous radical prostatectomy samples (considered as positive; only one sample from 
patients with two cancerous samples was utilized) resulted in area under the curve (AUC) 
values varied between 0.74 and 0.93 (Table 9). Furthermore, a comparison of CP 
samples (considered as negative) with histologically benign radical prostatectomy 
samples (considered as positive) using a single value of mRNA expression of each gene 
for each patient resulted in comparable AUC values varied between 0.69 and 0.92 (Table 
9). The similar predictive power of these genes using either histologically benign or 
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cancerous radical prostatectomy samples could be explained by the cancer field effect 
and molecular alterations in tissue samples that appear histologically benign.  
Table 9. The table presents the AUC values for each gene in the ROC analyses. 
(C) Area Under the Curve table 
Target mRNA RP-PCa (only one sample per patient, 
n=59) vs. CP (n=19) 
RP-Be (only one sample per patient, 
n=74) vs. CP (n=19) 
KLK3 0.740 0.709 
RHOU 0.773 0.761 
ACSM1 0.921 0.910 
CACNA1D 0.839 0.784 
LMNB1 0.789 0.751 
TDRD1 0.830 0.747 
PLA2G7 0.935 0.927 
DLX1 0.783 0.698 
SPON2 0.863 0.804 
 
Figure 6. ROC analyses for KLK3 mRNA levels and expression levels of 8 target mRNAs with 
cases classified as having cancer or not. To simplify the analyses for the patients with two 
cancerous/benign samples, a single value of mRNA expression of each gene for each patient, 
consistently from the right lobe of the prostate, was chosen. A. RP-PCa samples were considered 
as positive samples and compared with all CP samples (defined as negative); high sensitivity and 
specificity was observed for all eight biomarkers.  B. RP-Be samples were considered as positive 
samples and compared with all CP samples (defined as negative). (Figure from original 
publication III) 
A statistically significant difference was observed for candidate gene expression 
between normal prostate samples and malignant PCa samples. On the basis of clinical 
validation results and the association of the expression of target genes with 
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most informative for prognostic applications. An application of SPON2 as a novel 
biomarker for the detection of PCa and CRPC has recently been reported (Lucarelli et 
al., 2013; Barbieri, 2013; Qian et al., 2012). Furthermore, the overexpression of PLA2G7 
and TDRD1 in PCa and the association of PLA2G7 with aggressive forms of PCa have 
been reported earlier (Vainio et al., 2011a; Vainio et al., 2011b; Shaikhibrahim et al., 
2013; Massoner et al., 2013; Bertilsson et al., 2012).  
4.3.2. Knockdown with siRNA transfection and its effects on invasion and 
motility of PC-3 cells 
Compared to LNCaP and VCaP cells, a higher knockdown efficacy was observed in PC-
3 cells. On the basis of in silico analysis results, all of the selected candidate genes, with 
the exception of SPON2, were expressed in PC-3 cells. Hiperfect was used as 
transfection reagent, and qRT-PCR measurement revealed 70-95% knockdown levels 
for different genes either individually or combined in a siRNA pool. For all the eight 
genes, with the exception of ACSM1, a single siRNA, superior to pooled siRNA, was 
shown to be the most effective for transfection. The most effective siRNA (single or 
pooled), was selected for all further experiments. 
The comparison of wound healing experiment results between PC-3 cells transfected by 
different genes’ siRNA and either scrambled siRNA-transfected or untreated (mock 
transfected) PC-3 cells revealed a strong and reproducible effect on cell motility and 
migration only for RHOU gene. A stimulation of the T-ALL cell migration by an 
upregulation of RHOU that could contribute to enhanced motility and dissemination of 
leukaemia cells has been previously reported (Bhavsar et al., 2013). Similar effects could 
promote the aggressive and invasive properties of advanced PCa.  
4.3.3. Effect of gene knockdown on PC-3 cell morphology in 3D model 
Ten days after transferring the cells to a 3D culture, the resulting tumor organoid cells were 
stained with Calcein AM live cell dye (ThermoFisher, USA) and ethidium homodimer 1 
(EthD-1) that stains dead and apoptotic cells. Confocal images were then taken using a 
spinning disc. After noise filtering and image segmentation, a total of 26 different 
morphological parameters were evaluated using Automated Morphometric Image Data 
Analysis (AMIDA) (Harma et al., 2014). The parameters are particularly informative for 
the growth, differentiation, invasive properties, and multicellular organization of tumor 
structures. The effects of knockdown by siRNA on five of the more important parameters 
(area, density, MaxApp, roughness, and roundness) were investigated. 
ACSM1 (acyl-CoA synthetase medium-chain family member 1) has not been previously 
associated with PCa progression. Silencing ASCM1 resulted in weak morphologic 
effects and a mild reduction of invasive features (increased area and roundness and 
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decreased roughness compared to scrambled samples). ACSM1 has been reported as a 
potential marker for the invasive apocrine subtype of breast cancer which is associated 
with AR+ status and poor differentiation (Bockmayr et al., 2013; Celis et al., 2008; Celis 
et al., 2009).  
CACNA1Ds (calcium channel, voltage-dependent, L-type, alpha 1D subunits) are 
calcium channels involved in the entry of calcium ions into the cells and control a variety 
of calcium-dependent processes, such as gene expression. The role of CACNA1D in PCa 
cell growth promotion and proliferation (Chen et al., 2014) and in castration-resistant 
cancer progression (Loughlin, 2014) has been previously reported. 
In our study, the silencing of CACNA1D resulted in morphologic effects including the 
blocking of invasive structures and growth inhibition (increased area and roundness, and 
decreased roughness and MaxApp, compared to cells treated with scrambled siRNA). 
DLX1 (distal-less homeobox 1) gene encodes a transcription factor similar to the 
Drosophila distal-less gene. An overexpression of DLX1 in PCa has been published 
(Leyten et al., 2015; Pascal et al., 2009; Altintas et al., 2013) and it was confirmed by 
our clinical validation results. The silencing of DLX1 increased the cell density and 
roundness, but it decreased the area, MaxApp, and roughness parameters in comparison 
to cells treated with scrambled siRNA. 
LMNB1 (lamin B1) is a member of the lamin family that are highly conserved in 
evolution and involved in nuclear stability, chromatin structure, and gene expression. A 
reduced protein expression of LMNB1 in colon cancers (Moss et al., 1999) and a 
declined mRNA expression of LMNB1 in association with poor clinical outcome in 
breast cancer have been reported (Wazir et al., 2013).  In our work, we found that the 
expression of LMNB1 is increased in PCa samples compared to noncancerous samples. 
Furthermore, an overexpression of LMNB1 in human pancreatic cancer and its 
association with an increased incidence of distant metastasis and poor prognosis has been 
previously reported (Li et al., 2013). An analysis of AMIDA parameters revealed that 
LMNB1 silencing results in increased area, roundness, and MaxApp and decreased 
roughness compared to cells treated with scrambled siRNA. 
PLA2G7 (phospholipase A2, group VII) also known as PAFAH (plasma platelet-activating 
factor acetylhydrolase) is involved in the hydrolysis of phospholipids into fatty acids and 
other lipophilic molecules. As the association of PLA2G7 with aggressive PCa and its 
usefulness as a biomarker and drug target has been reported earlier (Vainio et al., 2011b; 
Bertilsson et al., 2012), it was selected as a positive control gene for our study. Silencing 
PLA2G7 in PC-3 cells resulted in increased density and roundness and decreased area, 
MaxApp and roughness compared to PC-3 cells treated with scrambled siRNA.  
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RHOU (ras homolog family member U) is a member of the Rho family of GTPases that 
acts upstream of PAK1 regulating the actin cytoskeleton and adhesion turnover, and 
increasing cell migration (Ory, Brazier and Blangy, 2007). The association of RHOU 
with PCa progression has not been reported earlier. In this study, the silencing of RHOU 
in PC-3 cells resulted in increased area, roundness and density, and decreased MaxApp 
and roughness when compared with PC-3 cells treated with scrambled siRNA. 
SPON2 (spondin 2) is an extracellular matrix protein-coding gene. SPON2 is not 
expressed in PC-3 cells, and was therefore used as a negative control; there was no 
difference in selected parameters between SPON2 knockdown and scrambled siRNA-
treated PC-3 cells. 
The usefulness of measuring TDRD1 (tudor domain containing 1) expression in urine 
samples in the early diagnosis of patients with clinically significant PCa has been 
reported (Leyten et al., 2015). Furthermore, the role of TDRD1 promoter methylation 
and its usefulness as an independent predictor of biochemical recurrence in high-risk 
PCa patients has been reported (Litovkin et al., 2014). In our study, the silencing of 
TDRD1 gene in PC-3 cells resulted in increased area and MaxApp, and decreased density 
and roundness in comparison with PC-3 scrambled siRNA treated PC-3 cells.  
The highest cytotoxic phenotypic effects were observed upon silencing DLX1 and 
PLA2G7, which resulted in a characteristic and significantly decreased area, roughness, 
and MaxApp in addition to an increased roundness and density compared to scrambled 
control-transfected cells. Taken together, these results indicate a generation of small, 
poorly proliferative, and non-invasive organoids that are essentially growth-arrested. 
Furthermore, the silencing of RHOU, ACSM1, and CACNA1D resulted in a noticeable, 
but not entirely specific inhibition of pro-invasive features (reduced MaxApp and 
roughness), combined with a strongly increased roundness; however, a less prominent 
reduction of cell growth (area) was observed. 
The results of this study provide evidence for these eight candidate genes as potential 
biomarkers in the diagnosis and prognosis of PCa.  Furthermore, the functional study 
results revealed the putative significance of these genes in disease-relevant processes. 
4.4. Expression of 11 biomarker genes in apparently benign tissue 
samples (IV) 
In this study we investigated the informative value of measuring 11 genes’ expression 
levels by qRT-PCR in biopsy cores retrieved from apparently non-cancerous areas. The 
genes were selected on the basis of the results in our previous studies that showed 
statistically significant differences in gene expression in histologically benign tissues 
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from men with and without PCa. The expression of ACSM1, AMACR, CACNA1D, 
DLX1, PCA3, PLA2G7, RHOU, SPINK1, SPON2, TMPRSS2-ERG, and TDRD1 in 
addition to KLK3 (as positive control) was measured in 99 prostate biopsies taken from 
apparently benign areas (as targeted by MRI) from men with a clinical suspicion of PCa. 
The expression of ACSM1, AMACR, CACNA1D, KLK3, PLA2G7, SPON2, and TDRD1 
RNAs were detected in all 99 samples, whereas PCA3 and SPINK1 were detected in 
96% of the samples from men without PCa and 100% and 98% of the samples from men 
with PCa, respectively; RHOU, DLX, and TMPRSS2-ERG mRNAs were detected less 
frequently. The expression of KLK3 was the highest among the 11 candidate genes and 
the expression levels of DLX1 and TMPRSS2-ERG were the lowest (Figure 7). Only the 
expression of TDRD1 showed a statistically significant difference between men with and 
without a PCa diagnosis (p=0.029). Furthermore, Fisher’s exact test revealed a 
significant difference in the detection of TMPRSS2-ERG (any variant) between men with 
and without PCa (p=0.035).  
 
Figure 7. Expression levels of 11 genes in biopsies from men with (green boxes) and without 
(blue boxes) a diagnosed PCa at biopsy. Boxes show the interquartile range, with the line in the 
middle denoting the median value. (Figure from original publication IV) 
Furthermore, the expression of TDRD1 was statistically significant when men with 
aggressive PCa (patients with Gleason sum 7–10 at biopsy) were compared with men 
with low-risk PCa (Gleason sum < 7 at biopsy). Moreover, the expression of TMPRSS2-
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ERG mRNAs was detected in 26/53 (49.1%) aggressive cases and in 6/46 (13.0%) less 
aggressive or healthy cases (Fisher’s exact test, p<0.001). The percentage of free PSA 
in serum showed a statistically significant difference in men with PCa vs. men without 
(Mann-Whitney U test, p<0.001). Furthermore a statistically significant difference was 
observed for the percentage of free PSA in serum, in men with PCa of Gleason sum 7 or 
higher vs. men with lower risk PCa or no PCa (Mann-Whitney U test, p=0.002). There 
was no significant difference in total PSA between the above-mentioned groups. There 
was no statistically significant difference for any of the candidate genes’ expressions 
between men with pT2 stage and men with pT3 stage of PCa.  
As the reason of choosing these 11 genes for this study was their capability to 
discriminate between histologically benign tissues from men with and without PCa, the 
fact that only two of the candidate RNAs showed such capability in this study is in 
contrast with our hypothesis. This could be explained by differences in samples without 
PCa that were used in these studies. Here, biopsies from individuals with clinical 
suspicion of PCa were used, but in previous studies cystoprostatectomy samples 
obtained from men with no clinical suspicion of PCa were used as non-cancerous cases. 
Another possibility could be the presence of microfoci of cancer in the biopsy core that 
remained undetected in MRI and systematic biopsies. Moreover, using different methods 
and RNA preservative solutions (the commercial RNA stabilizing solution, RNAlater, 
in this study compared to fresh-freezing and GITC solution used in previous studies) 
could have caused the differences in the results.  
The improvement of the diagnosis and prognosis potency of single biomarkers by 
combining them together and using a multivariate analysis has been previously reported 
(Cuzick et al., 2011; Erho et al., 2013; Wu et al., 2013). In accordance to these studies, 
we found that a combination of 11 target genes with clinical data (serum PSA, F/T PSA 
percentage, and prostate volume) and a multivariate analysis using logistic regression 
classifier with L2-norm regularization (Buitinck et al., 2013) and leave-pair-out cross-
validation (LPOCV) (Airola et al., 2011) improved the potency of discrimination 
between aggressive PCas and non-aggressive PCas, and non-cancerous prostates, as well 
as T3 PCas and T2 PCas or non-cancerous prostates, compared with analyses utilizing 
each of the 15 features individually (Table 10). 
The transcriptional activation of TDRD1 in TMPRS2-ERG positive PCa and the 
association of upregulation of TDRD1 with the overexpression of ERG in primary PCa 
have been previously reported (Kacprzyk et al., 2013; Boormans et al., 2013). In this 
study, we found that TDRD1 mRNA levels were 1.8 times higher in TMPRSS2-ERG 
positive samples (Mann-Whitney U test, p=0.003). 
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Table 10. Area under the curve (AUC) values of receiver operating characteristic (ROC) analyses 
for prostate volume, serum PSA levels, free-to-total PSA ratios in serum, and levels of 12 target 
mRNAs in tissue individually and in multivariate analyses. The analyses included those 80 men 
for whom all 15 features were available. Cases were classified according to disease 
aggressiveness and invasion. Clinically significant aggressive PCa was defined as Gleason sum 







Area under the curve 
PCa of Gleason sum 







T3 vs T2  
and healthy 
Prostate volume 0.646 0.746 
Total PSA in serum 0.566 0.743 
F/T1 PSA % in serum 0.703 0.609 
ACSM1 mRNA  0.501 0.501 
AMACR mRNA 0.520 0.532 
CACNA1D mRNA 0.575 0.562 
DLX1 mRNA 0.518 0.584 
KLK3 mRNA 0.534 0.511 
PCA3 mRNA 0.560 0.550 
   
PLA2G7 mRNA  0.555 0.586 
RHOU mRNA 0.521 0.539 
SPINK1 mRNA 0.514 0.586 
SPON2 mRNA 0.521 0.519 
TDRD1 mRNA 0.649 0.581 
Any detectable TMPRSS2-ERG mRNA 0.683 0.572 
Multivariate LPOCV* using clinical 
parameters (total PSA, F/T PSA% and 
prostate volume) 
0.684 0.867 





This doctoral work was planned to identify novel diagnosis and prognosis biomarkers 
for PCa. In this thesis, the potential of bioinformatic tools, microarray datasets, qRT-
PCR, and siRNA technique were combined to identify and validate novel biomarkers for 
PCa. 
It can be concluded on the basis of the original publications that: 
I. Applying LCC reporter probes as a new detection method provides the same 
sensitivity and specificity as the previously reported HELC technique. The use of 
either LCC or HELC method resulted in the same limit of detection for KLK3 
standard series (1 copy/μl template). Quantifiable levels of KLK3 mRNA were 
seen in all of the prostate tissue samples, whereas this was true for only one of the 
blood samples from PCa patients. Therefore, it could be concluded that blood 
samples from patients with a localized PCa are not suitable for CTC and gene 
expression studies.  
II. Compared to CP samples, AMACR mRNA expression was similarly upregulated 
in all of the RP-Be and RP-PCa samples, which indicates a global overexpression 
of AMACR in prostates with carcinoma. The overexpression of AMACR in 
histologically benign areas of prostates harboring cancer was also detected in the 
preliminary, but systematic, cross-section study here. Therefore, it could be 
concluded that an AMACR mRNA measurement with a qRT-PCR assay could be 
useful for patients with false negative biopsies when assessing their cancer risk.  
III. The knockdown by siRNA resulted in a cytotoxic effect for DLX1, PLA2G7, and 
RHOU silencing; furthermore, a cell invasion alteration was caused by PLA2G7, 
RHOU, ACSM1, and CACNA1D silencing in 3D, as well as cell-motility blocking 
effects by PLA2G7 and RHOU silencing in 2D. A further statistically significant 
mRNA overexpression was observed for all eight genes in malignant PCa samples 
compared to normal prostate samples. Additionally, significant differences were 
observed in low versus high Gleason grades (for PLA2G7), PSA relapse versus no 
relapse (for SPON2), and low versus high TNM stages (for CACNA1D and DLX1). 
These results indicate the usefulness of bioinformatic data mining in combination 
with clinical biomarker validation by qRT-PCR and the functional evaluation of 
candidate genes in the identification of novel disease-relevant biomarkers. The 
eight novel biomarkers studied here show the potential to become useful 
biomarkers for PCa diagnosis. Furthermore, the possibility of using some of these 
genes as therapeutic targets could be considered in future studies.  
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IV. Measuring the mRNA expression of TDRD1 and TMPRSS2-ERG as single 
markers in apparently benign prostate tissue biopsies from men with a clinical 
suspicion of PCa was useful in discriminating between men with and without PCa. 
However, utilizing a multivariate analysis using 12 genes’ RNA expression in 
combination with serum PSA, F/T PSA, and prostate volume outperformed each 
individual marker in distinguishing aggressive PCa from indolent disease. This 
result provides evidence that multiplex approaches and multivariate analyses may 
improve the diagnostic and prognostic potency of the markers in comparison with 
the use of a single biomarker. 
Our results support the previous findings that a single biomarker does not provide 
sufficient sensitivity and specificity for PCa diagnosis. Combining several different RT-
PCR assays into a single multiplex RT-PCR reaction is challenging, and a careful design 
and optimization of the assays are necessary. The optimization and validation of the 
assays could be costly and time consuming. Increasing the number of the targets will 
increase the cost and time involved. Furthermore, due to the limited number of available 
filters in RT-PCR instruments only a limited number of the target genes could be 
included. An alternative for multiplex approach would be the application of the statistical 
models and multivariate analyses to combine the separate assay results into an 
informative method.  Several studies have investigated the predictive value of different 
gene expression panels in PCa. A genomic classifier including 22 genes that predicts the 
early metastasis of PCa following radical prostatectomy is commercially available by 
Decipher ® (USA) (Erho et al., 2013). There are also several other commercially 
available gene expression panel tests by Prolaris® (USA) for the prediction of metastatic 
progression, mortality, biochemical recurrence, survival, and treatment failure (Cuzick 
et al., 2011; Cooperberg et al., 2013; Cuzick et al., 2012; Bishoff et al., 2014; Freedland 
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